<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004139.pub2" GROUP_ID="HAEMATOL" ID="360802070211123804" MERGED_FROM="" MODIFIED="2012-03-13 13:36:42 +0100" MODIFIED_BY="Andrea Will" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.4" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.0">
<COVER_SHEET MODIFIED="2012-03-13 13:36:42 +0100" MODIFIED_BY="Andrea Will">
<TITLE MODIFIED="2009-02-12 16:03:57 +0100" MODIFIED_BY="[Empty name]">Colony-stimulating factors for prevention of myelosuppressive therapy-induced febrile neutropenia in children with acute lymphoblastic leukaemia</TITLE>
<CONTACT>
<PERSON ID="13782" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Emma</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Sasse</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>emma.sasse@uol.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Internal Medicine</DEPARTMENT>
<ORGANISATION>UNICAMP (Universidade Estadual de Campinas)</ORGANISATION>
<ADDRESS_1>Av Dr. Luiz de Tella, 1515</ADDRESS_1>
<ADDRESS_2>Cidade Universitaria</ADDRESS_2>
<CITY>Campinas</CITY>
<ZIP>13083 000</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 19 32878866</PHONE_1>
<PHONE_2/>
<FAX_1>+55 19 32878017</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-03-13 13:26:58 +0100" MODIFIED_BY="Andrea Will">
<PERSON ID="13782" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Emma</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Sasse</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>emma.sasse@uol.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Internal Medicine</DEPARTMENT>
<ORGANISATION>UNICAMP (Universidade Estadual de Campinas)</ORGANISATION>
<ADDRESS_1>Av Dr. Luiz de Tella, 1515</ADDRESS_1>
<ADDRESS_2>Cidade Universitaria</ADDRESS_2>
<CITY>Campinas</CITY>
<ZIP>13083 000</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 19 32878866</PHONE_1>
<PHONE_2/>
<FAX_1>+55 19 32878017</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13783" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Andre</FIRST_NAME>
<MIDDLE_INITIALS>D</MIDDLE_INITIALS>
<LAST_NAME>Sasse</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>andre@sasse.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Internal Medicine</DEPARTMENT>
<ORGANISATION>UNICAMP (Universidade Estadual de Campinas)</ORGANISATION>
<ADDRESS_1>Av Dr. Luiz de Tella 1515</ADDRESS_1>
<ADDRESS_2>Cidade Universitaria</ADDRESS_2>
<CITY>Campinas</CITY>
<ZIP>13083 000</ZIP>
<REGION>Sao Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 19 32878866</PHONE_1>
<PHONE_2/>
<FAX_1>+55 19 32878017</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13746" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Sílvia</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>Brandalise</LAST_NAME>
<SUFFIX/>
<POSITION>Center Director</POSITION>
<EMAIL_1>silvia@boldrini.org.br</EMAIL_1>
<EMAIL_2/>
<URL>www.boldrini.org</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Centro Infantil Boldrini</ORGANISATION>
<ADDRESS_1>Centro Infantil Boldrini, Rua Gabriel Porto, 1270 Cidade Univesitária</ADDRESS_1>
<ADDRESS_2/>
<CITY>Campinas</CITY>
<ZIP>13083-210</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 19 3787 5002</PHONE_1>
<PHONE_2>+55 19 3787 5001</PHONE_2>
<FAX_1>+55 19 3289 3571</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13680" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Otavio</FIRST_NAME>
<MIDDLE_INITIALS>Augusto Camara</MIDDLE_INITIALS>
<LAST_NAME>Clark</LAST_NAME>
<SUFFIX/>
<POSITION>Chief of Oncology Service</POSITION>
<EMAIL_1>clark@evidencias.com.br</EMAIL_1>
<EMAIL_2>otavioclark@uol.com.br</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>EVIDENCIAS</DEPARTMENT>
<ORGANISATION>Scientific Solutions in Healthcare</ORGANISATION>
<ADDRESS_1>Av. Dr. Luis de Tella</ADDRESS_1>
<ADDRESS_2>Campinas</ADDRESS_2>
<CITY>San Paolo</CITY>
<ZIP>1570</ZIP>
<REGION/>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 193 287 8310</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17217" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sue</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Richards</LAST_NAME>
<SUFFIX>Dr Phil</SUFFIX>
<POSITION>Senior Statistician</POSITION>
<EMAIL_1>sue.richards@ctsu.ox.ac.uk</EMAIL_1>
<EMAIL_2>suerichardsnow@yahoo.co.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE>+44 77 9936 4371</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Clinical Trials Services Unit</DEPARTMENT>
<ORGANISATION>Oxford University</ORGANISATION>
<ADDRESS_1>Woodstock Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Oxford</CITY>
<ZIP>OX2 6HE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 743 863</PHONE_1>
<PHONE_2>+44 1685 881936</PHONE_2>
<FAX_1>+ 44 1865-743986</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-10-17 10:32:37 +0200" MODIFIED_BY="Nicole Skoetz">
<UP_TO_DATE>
<DATE DAY="12" MONTH="10" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="18" MONTH="9" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="13" MONTH="10" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2012-03-13 13:36:42 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-03-13 13:35:16 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>Additional tables linked to text.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-03-13 13:36:42 +0100" MODIFIED_BY="Nicole Skoetz">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-03-13 13:36:30 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Review updated with no change in conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-03-13 13:36:42 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>New search for clinical trials completed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-03-13 13:34:47 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-03-13 13:34:22 +0100" MODIFIED_BY="Nicole Skoetz">
<SUMMARY MODIFIED="2009-02-12 16:04:33 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Prophylactic administration of colony-stimulating factors reduces hospital stay and risk of infections in children with acute lymphoblastic leukaemia</TITLE>
<SUMMARY_BODY MODIFIED="2009-02-12 16:04:33 +0100" MODIFIED_BY="[Empty name]">
<P>The authors evaluated the efficacy of adding colony-stimulating factors (CSF) after chemotherapy in children with acute lymphoblastic leukaemia (ALL) to prevent febrile neutropenia, which is a potentially life-threatening side effect of treatment.<BR/>
<BR/>There is a lack of studies to determine the best CSF dose for children and only a small number of RCTs evaluating the role of CSF in children's ALL. The prophylactic administration of CSF reduces hospital stay, and risk of infections. The authors did not find evidence that CSF reduces febrile neutropenia episodes, their duration, or treatment delays in children with ALL undergoing chemotherapy. Follow up was too short to provide useful information on any possible effect on relapse or survival.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-05-13 08:57:57 +0200" MODIFIED_BY="Nicole Skoetz">
<ABS_BACKGROUND MODIFIED="2009-02-12 16:03:48 +0100" MODIFIED_BY="[Empty name]">
<P>Acute lymphoblastic leukaemia (ALL) is the most common cancer in childhood and febrile neutropenia is a potentially life-threatening side effect of its treatment. Current treatment consists of supportive care plus antibiotics. Clinical trials have attempted to evaluate the use of colony-stimulating factors (CSF) as additional therapy to prevent febrile neutropenia in children with ALL. Individual trials have not demonstrated significant benefit. Systematic reviews provide the most reliable assessment and the best recommendations for practice.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-05-13 08:57:57 +0200" MODIFIED_BY="Nicole Skoetz">
<P>To evaluate the safety and effectiveness of the addition of granulocyte colony-stimulating factors (G-CSF) or granulocyte macrophage colony-stimulating factors (GM-CSF) to myelosuppressive chemotherapy in children with ALL in an effort to prevent the development of febrile neutropenia. Evaluation of number of febrile neutropenia episodes, length to neutrophil count recovery, incidence and length of hospitalisation, number of infectious disease episodes, incidence and length of treatment delays, side effects (flu-like syndrome, bone pain and allergic reaction), relapse and overall mortality (death).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-02-12 16:04:02 +0100" MODIFIED_BY="[Empty name]">
<P>The search covered the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CANCERLIT, LILACS, and SciElo. We manually searched records of conference proceedings of ASCO and ASH from 1985 to 2003 and used the electronic databases of the ASCO and ASH web sites to search for abstracts from 2003 to September 2008, as well as databases of ongoing trials. We consulted experts and scanned references from the relevant articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We looked for randomised controlled trials (RCTs) comparing CSF with placebo or no treatment as primary or secondary prophylaxis to prevent febrile neutropenia in children with ALL.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-02-12 16:04:09 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently selected and critically appraised studies and extracted relevant data. The end points of interest were:<BR/>
<BR/>* Primary end points: number of febrile neutropenia episodes and overall mortality (death)<BR/>* Secondary end points: time to neutrophil count recovery, incidence and length of hospitalisation, number of infectious diseases episodes, incidence and length of treatment delays, side effects (flu-like syndrome, bone pain and allergic reaction) and relapse.<BR/>
<BR/>We conducted a meta-analysis of these end points and expressed the results as Peto odds ratios. For continuous outcomes we calculated a weighted mean difference and a standardised mean difference. For count data, we conducted a meta-analysis of the logarithms of the rate ratios using generic inverse variance.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-02-12 16:04:15 +0100" MODIFIED_BY="[Empty name]">
<P>We scanned more than 6800 citations and included six studies with a total of 333 participants in the analysis. There were insufficient data to assess the effect on survival. The use of CSF significantly reduced the number of episodes of febrile neutropenia episodes (Rate Ratio = 0.63; 95% confidence interval (CI) 0.46 to 0.85; P = 0.003, with substantial heterogeneity), the length of hospitalisation (weighted mean difference (WMD) = -1.58; 95% CI -3.00 to -0.15; P = 0.03), and number of infectious disease episodes (Rate Ratio = 0.56; 95% CI 0.39 to 0.80; P = 0.002). Despite these results, CSF did not influence the length of episodes of neutropenia (WMD = -1.11; 95% CI -3.55 to 1.32; P = 0.4) or delays in chemotherapy courses (Rate Ratio = 0.75; 95% CI 0.47 to 1.20; P = 0.23) .</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-02-12 16:04:25 +0100" MODIFIED_BY="[Empty name]">
<P>Children with ALL treated with CSF benefit from shorter hospitalisation and fewer infections. However, there was no evidence of shortened duration of neutropenia nor fewer treatment delays. There was also no useful information about survival.<BR/>
<BR/>The role of CSF in the context of febrile neutropenia episodes is still uncertain. Although current data show statistical benefit with CSF use, substantial heterogeneity between included trials does not allow this conclusion.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-03-13 13:34:22 +0100" MODIFIED_BY="Nicole Skoetz">
<BACKGROUND MODIFIED="2009-02-12 16:04:33 +0100" MODIFIED_BY="[Empty name]">
<P>The administration of more intensive chemotherapy (<LINK REF="REF-Pui-1998" TYPE="REFERENCE">Pui 1998</LINK>; <LINK REF="REF-Pui-2001" TYPE="REFERENCE">Pui 2001</LINK>) combined with advances in supportive care (<LINK REF="REF-Gmur-1991" TYPE="REFERENCE">Gmur 1991</LINK>; <LINK REF="REF-Kaushansky-2000" TYPE="REFERENCE">Kaushansky 2000</LINK>; <LINK REF="REF-Kritz-1991" TYPE="REFERENCE">Kritz 1991</LINK>; <LINK REF="REF-Lok-1994" TYPE="REFERENCE">Lok 1994</LINK>) have led to improved survival rates among children with acute lymphoblastic leukaemia (ALL). Chemotherapy-induced febrile neutropenia remains a life-threatening complication for patients with cancer and causes prolonged hospitalisation (<LINK REF="REF-Alexander-1999" TYPE="REFERENCE">Alexander 1999</LINK>; <LINK REF="REF-Chanock-1996" TYPE="REFERENCE">Chanock 1996</LINK>; <LINK REF="REF-Lee-1998" TYPE="REFERENCE">Lee 1998</LINK>; <LINK REF="REF-Petrilli-1993" TYPE="REFERENCE">Petrilli 1993</LINK>; <LINK REF="REF-Pizzo-1982" TYPE="REFERENCE">Pizzo 1982</LINK>; <LINK REF="REF-Pizzo-1991" TYPE="REFERENCE">Pizzo 1991</LINK>), increased costs of therapy (<LINK REF="REF-Aquino-1997" TYPE="REFERENCE">Aquino 1997</LINK>; <LINK REF="REF-Aquino-1997" TYPE="REFERENCE">Aquino 1997</LINK>(2); <LINK REF="REF-Bash-1994" TYPE="REFERENCE">Bash 1994</LINK>; <LINK REF="REF-Elting-2002" TYPE="REFERENCE">Elting 2002</LINK>; <LINK REF="REF-Rosenman-2002" TYPE="REFERENCE">Rosenman 2002</LINK>) and delay of chemotherapy courses (<LINK REF="REF-Pizzo-1999" TYPE="REFERENCE">Pizzo 1999</LINK>). Current standard practices of instituting empiric broad-spectrum antibiotic therapy in the setting of fever with neutropenia have reduced mortality rates to around 2% to 5% (<LINK REF="REF-Alexander-1999" TYPE="REFERENCE">Alexander 1999</LINK>; <LINK REF="REF-Pizzo-1993" TYPE="REFERENCE">Pizzo 1993</LINK>). The use of hematopoietic growth factors (<LINK REF="REF-Vose-1995" TYPE="REFERENCE">Vose 1995</LINK>) has led to shorter periods of chemotherapy-induced neutropenia (<LINK REF="REF-Furman-1991" TYPE="REFERENCE">Furman 1991</LINK>; <LINK REF="STD-Laver-1998" TYPE="STUDY">Laver 1998</LINK>; <LINK REF="REF-Lifton-1996" TYPE="REFERENCE">Lifton 1996</LINK>; <LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>; <LINK REF="REF-Riikonen-1994" TYPE="REFERENCE">Riikonen 1994</LINK>; <LINK REF="REF-Saarinen-1992" TYPE="REFERENCE">Saarinen 1992</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>), post-transplant neutropenia after both allogeneic and autologous bone marrow transplants (<LINK REF="REF-Madero-1995" TYPE="REFERENCE">Madero 1995</LINK>; <LINK REF="REF-Nemunaitis-1992" TYPE="REFERENCE">Nemunaitis 1992</LINK>; <LINK REF="REF-Saarinen-1996" TYPE="REFERENCE">Saarinen 1996</LINK>) and neutropenic fever (<LINK REF="REF-Riikonen-1994" TYPE="REFERENCE">Riikonen 1994</LINK>).<BR/>
<BR/>Colony-stimulating factors (CSF) are a family of cytokines that regulate the proliferation and differentiation of hematopoietic cells (<LINK REF="REF-Griffin-2001" TYPE="REFERENCE">Griffin 2001</LINK>). Among them, granulocyte colony stimulating factors (G-CSF) and granulocyte-macrophage colony stimulating factors (GM-CSF) have been tested in clinical trials involving participants with febrile neutropenia. G-CSF regulates the production of the neutrophil lineage. The administration of G-CSF results in a dose-dependent increase in circulating neutrophils (<LINK REF="REF-Griffin-2001" TYPE="REFERENCE">Griffin 2001</LINK>; <LINK REF="REF-Petros-2001" TYPE="REFERENCE">Petros 2001</LINK>). This is mainly due to a reduced transit time from stem cell to mature neutrophil (<LINK REF="REF-Griffin-2001" TYPE="REFERENCE">Griffin 2001</LINK>). GM-CSF is a growth factor for the myeloid lineage that stimulates the growth of granulocytes, macrophages and eosinophil colonies (<LINK REF="REF-Griffin-2001" TYPE="REFERENCE">Griffin 2001</LINK>; <LINK REF="REF-Petros-2001" TYPE="REFERENCE">Petros 2001</LINK>). Administration of GM-CSF results in a dose-dependent increase in neutrophils, eosinophils, macrophages and sometimes lymphocytes (<LINK REF="REF-Griffin-2001" TYPE="REFERENCE">Griffin 2001</LINK>; <LINK REF="REF-Petros-2001" TYPE="REFERENCE">Petros 2001</LINK>).<BR/>
<BR/>CSF can be used in two prophylactic ways. In primary prophylaxis, CSF is used before the onset of any neutropenia or febrile neutropenia episode, while secondary prophylaxis is the use of CSF after at least one episode of febrile neutropenia to prevent a new episode or to avoid dose reductions and delays in chemotherapy courses (<LINK REF="REF-Ozer-2000" TYPE="REFERENCE">Ozer 2000</LINK>).<BR/>
<BR/>A variety of phase I and phase II studies in children with cancer receiving intensive chemotherapy have documented that primary administration of G-CSF reduces the duration of neutropenia, lowers rates of neutropenic fever, decreases use of antibiotics and diminishes the need for hospitalisation compared to historical control subjects who did not receive G-CSF (<LINK REF="REF-Lifton-1996" TYPE="REFERENCE">Lifton 1996</LINK>; <LINK REF="REF-Welte-1997" TYPE="REFERENCE">Welte 1997</LINK>). Other larger RCTs showed a lower incidence of febrile neutropenia and confirmed infection as well as a shorter duration of total antibiotic use compared with those receiving a placebo (<LINK REF="REF-Riikonen-1995" TYPE="REFERENCE">Riikonen 1995</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>). However, not all studies have shown a benefit from the use of G-CSF (<LINK REF="STD-Laver-1998" TYPE="STUDY">Laver 1998</LINK>; <LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>; <LINK REF="REF-Rubino-1998" TYPE="REFERENCE">Rubino 1998</LINK>). RCTs of GM-CSF administered in supportive care in childhood malignancies as primary prophylaxis of neutropenic fever have usually resulted in lesser duration or severity of neutropenia, but clinical benefits have not been as consistently positive as those observed with G-CSF (<LINK REF="REF-Armitage-1998" TYPE="REFERENCE">Armitage 1998</LINK>; <LINK REF="REF-Burdach-1995" TYPE="REFERENCE">Burdach 1995</LINK>; <LINK REF="REF-Lifton-1996" TYPE="REFERENCE">Lifton 1996</LINK>; <LINK REF="REF-Wexler-1996" TYPE="REFERENCE">Wexler 1996</LINK>). Although some RCTs have compared the prophylactic use of CSF with no treatment or placebo in children, none of these has shown a significant benefit (<LINK REF="REF-Lee-1998" TYPE="REFERENCE">Lee 1998</LINK>; <LINK REF="STD-Little-2002" TYPE="STUDY">Little 2002</LINK>; <LINK REF="STD-Ohno-1993" TYPE="STUDY">Ohno 1993</LINK>; <LINK REF="REF-Riikonen-1995" TYPE="REFERENCE">Riikonen 1995</LINK>; <LINK REF="REF-Wexler-1996" TYPE="REFERENCE">Wexler 1996</LINK>). The long-term benefits of using growth factors during intensive phases of ALL therapy remain controversial (<LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>). Moreover the safety of CSF is still not well established, as receptors for some CSFs found on the membranes of lymphoblastic cells (<LINK REF="REF-Inukai-1998" TYPE="REFERENCE">Inukai 1998</LINK>; <LINK REF="REF-Trus-2003" TYPE="REFERENCE">Trus 2003</LINK>; <LINK REF="REF-Benko-2001" TYPE="REFERENCE">Benko 2001</LINK>) could, hypothetically, influence treatment outcomes. For these reasons, as well as financial considerations, G-CSF and other growth factors are not routinely used in standard risk ALL regimens. They are more often administered in cases of bone marrow transplants and relapsed ALL and occasionally in front-line high-risk patients undergoing exceptionally intensive chemotherapy (<LINK REF="STD-Saarinen_x002d_Pihkala2000" TYPE="STUDY">Saarinen-Pihkala2000</LINK>). The routine use of these agents after lesser myelosuppressive chemotherapy is not supported by the literature. Therefore the use of CSF in prophylaxis is not uniform and depends on physician preference (<LINK REF="REF-Parsons-2000" TYPE="REFERENCE">Parsons 2000</LINK>) and available data (<LINK REF="REF-Ozer-2000" TYPE="REFERENCE">Ozer 2000</LINK>). The perception of high-dose intensity and anticipated toxicity of paediatric chemotherapeutic regimens also tend to promote CSF use (<LINK REF="REF-Parsons-2000" TYPE="REFERENCE">Parsons 2000</LINK>).<BR/>
<BR/>Such issues have led to reviews evaluating the role of CSFs in other types of haematological malignancies and populations. <LINK REF="REF-Bohlius-2008" TYPE="REFERENCE">Bohlius 2008</LINK> performed a systematic review to evaluate the role of G-CSF and GM-CSF in the prevention of adverse effects secondary to lymphoma treatment. Although there were reduced risks of neutropenia, febrile neutropenia and infection, there is still no evidence that G-CSF or GM-CSF provide a more favourable response rate, freedom of treatment failure or overall survival.<BR/>
<BR/>The lack of any conclusive data derived from seemingly conflicting studies of the prophylactic use of CSF to prevent myelosuppressive therapy-induced neutropenia in children with ALL demands a systematic review to equip clinicians with reliable data upon which to base clinical decisions.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-02-12 16:04:33 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the safety and effectiveness of the addition of G-CSF or GM-CSF to chemotherapy in children with ALL, in an effort to prevent the development of febrile neutropenia. In particular, we seek evaluation of the number of febrile neutropenia episodes, length of time to neutrophil count recovery, length of hospitalisation, number of infectious disease episodes, number of infectious diseases episodes, incidence and length of treatment delays, side effects (flu-like syndrome, bone pain and allergic reaction), relapse<BR/>and overall mortality (death).</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-02-12 16:30:34 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-02-12 16:04:33 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-02-12 16:04:33 +0100" MODIFIED_BY="[Empty name]">
<P>RCTs with a parallel design that compare CSF versus placebo or no treatment given prior to the installation of neutropenia related to chemotherapy in children with ALL. We included information from ongoing studies and interim analyses with the same design. There was no restriction on language of publication.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-02-12 16:04:33 +0100" MODIFIED_BY="[Empty name]">
<P>Children (0 to 18 years) with ALL receiving myelosuppressive chemotherapy, excluding situations related to bone marrow transplantation. We included trials with upper age range of 19, 20, or 21 where we could not obtain separate results for the 0 to 18 year age range.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-02-12 16:04:33 +0100" MODIFIED_BY="[Empty name]">
<P>The administration of CSF to prevent febrile neutropenia induced by chemotherapy in children with ALL, given concomitantly or after 24 to 48 hours, concluded the chemotherapy course as primary or secondary prophylaxis to prevent febrile neutropenia. G-CSF or GM-CSF administered subcutaneously in a dose of at least 5 mcg/kg body weight per day, given until absolute neutrophil counts reached more than 0.5 x 10<SUP>9</SUP>/L. We excluded trials of high-dose myeloablative chemotherapy regimens followed by bone marrow transplantation due to the length of severe neutropenia that differs considerably compared to standard dose regimens for paediatric ALL. We also excluded trials using CSF for treatment of febrile neutropenia because this is a different situation.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-02-12 16:04:33 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-02-12 16:04:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Number of febrile neutropenia episodes</LI>
<LI>Overall mortality (death)</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-02-12 16:04:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Time to neutrophil count recovery</LI>
<LI>Incidence and length of hospitalisation</LI>
<LI>Number of infectious diseases episodes</LI>
<LI>Incidence and length of treatment delays</LI>
<LI>Side effects (flu-like syndrome, bone pain and allergic reaction)</LI>
<LI>Relapse</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>We identified relevant trials in any language through:</P>
<ELECTRONIC_SEARCHES MODIFIED="2009-02-12 16:04:33 +0100" MODIFIED_BY="[Empty name]">
<P>We performed a wide search in the main computerised databases of interest from 1985 to 2008:</P>
<UL>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL)</LI>
<LI>Cancer Literature On line (CANCERLIT)</LI>
<LI>Excerpta Medica Database (EMBASE)</LI>
<LI>Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS)</LI>
<LI>Medilars Online (MEDLINE)</LI>
<LI>Scientific Electronic Library Online (SciELO)</LI>
<LI>American Society of Clinical Oncology Website (ASCO) - searched from 2003 to September 2008</LI>
<LI>American Society of Hematology Website (ASH) - searched from 2003 to September 2008</LI>
</UL>
<P>Search strategy in electronic databases: the methodological search strategy used in MEDLINE is that reported by <LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>. We used adaptations of this strategy in EMBASE (<LINK REF="REF-Egger-2001" TYPE="REFERENCE">Egger 2001</LINK>) and LILACS (<LINK REF="REF-Castro-1999" TYPE="REFERENCE">Castro 1999</LINK>) searches (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). For the ASCO and ASH websites we used combinations of terms used in MEDLINE.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Search of databases of ongoing trials</HEADING>
<P>We performed a search of the following databases:</P>
<UL>
<LI>Current Controlled Trials Register: http://www.controlled-trials.com;</LI>
<LI>European Organisation for Research and Treatment of Cancer (EORTC): http://www.eortc.be;</LI>
<LI>United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR): http://www.ctu;mrc.ac.uk/ukcccr/;</LI>
<LI>UK National Research Register of all NHS-funded research: http://www.doh.gov.uk/research/nrr.htm;</LI>
<LI>National Cancer Institute, America: http://www.cancertrials.nci.nih.gov/researchers/index.html;</LI>
<LI>National Cancer Institute, Canada: http://www.ctg.queensu.ca/ctg_home.htm;</LI>
<LI>National Health and Medical Council of Australia: http://www.ctc.usyd.edu.au/.</LI>
<LI>Cochrane Central Register of Controlled Trials: http://www.mrw.interscience.wiley.com/cochrane/cochrane_clcentral_articles_fs.html</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Contact</HEADING>
<P>We consulted experts in oncology and haematology about ongoing or currently unpublished studies. We also contacted Roche do Brasil (Brazilian division of La Roche Pharmaceuticals) and Aventis Pharma do Brasil (Brazilian division of Aventis Pharma) which are involved in the manufacture of CSF about ongoing or unpublished randomised trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Manual search</HEADING>
<P>We searched citations from identified trials and relevant review articles as well as conference proceedings until 2003 of the</P>
<UL>
<LI>American Society of Clinical Oncology (ASCO),</LI>
<LI>American Society of Hematology (ASH ),</LI>
<LI>European Society of Medical Oncology (ESMO).</LI>
</UL>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-02-12 16:30:34 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (ECS, OC) independently screened titles and abstracts of studies identified from the above sources. Where we found this to be unsatisfactory, we obtained a full text version for assessment. We resolved disagreements through a consensus meeting. We called upon a third author (ADS) to resolve disagreement where necessary.</P>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Two authors (ECS, OC) independently extracted the data from articles. For identification purposes, we used the name of the first author and the publication year. We extracted all data directly from the text or, where possible, made calculations based on the information available.<BR/>
<BR/>We extracted the following quality domains empirically linked to bias (<LINK REF="REF-Egger-2001" TYPE="REFERENCE">Egger 2001</LINK>): methods of randomisation, data regarding allocation concealment, blinding of patients, blinding of care-givers, blinding of outcome evaluators, description of withdrawals and drop-outs, details regarding intention-to-treat analysis, power analysis, and source of funding. We retrieved selected clinical outcomes and additional data.</P>
<SUBSECTION>
<HEADING LEVEL="4">Selected clinical outcomes and definitions</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary endpoints</HEADING>
<UL>
<LI>Number of febrile neutropenia episodes: we defined febrile neutropenia (<LINK REF="REF-Ozer-2000" TYPE="REFERENCE">Ozer 2000</LINK>) as oral temperature above 38.3ºC unrelated to transfusions associated with grade IV neutropenia (absolute neutrophil count (ANC) less than 500/mm<SUP>3</SUP>);</LI>
<LI>overall mortality or death: we included deaths related or not related to chemotherapy, use of CSF or progression of disease.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary endpoints</HEADING>
<UL>
<LI>Time to neutrophil count recovery: we considered the number of days needed for the ANC to rise from less than 500/mm<SUP>3</SUP> to 500/mm<SUP>3</SUP> after each course of chemotherapy.</LI>
<LI>Incidence and length of hospitalisation: we considered the number of episodes and days of hospitalisation due to chemotherapy infusions or any complication.</LI>
<LI>Number of infectious disease episodes: we considered an episode of infection as every objective sign of infection of any site confirmed by microbiologic assay or radiologic exam associated with compatible clinical signs in the groups studied.</LI>
<LI>Incidence and length of treatment delays: we defined an episode as delayed when a subsequent course of chemotherapy started after the scheduled day due to complications resulting from treatment. We determined the length of treatment delay to be the number of days elapsed since the originally scheduled start of a course of chemotherapy.</LI>
<LI>Side effects: we considered each episode of flu-like syndrome, bone pain, allergic reaction as a side effect related to CSF use and evaluated both groups.</LI>
<LI>Relapses: we considered the recurrence of ALL after positive response to myelosuppressive chemotherapy at any time after starting treatment.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Additional data evaluated in sub-group analysis</HEADING>
<UL>
<LI>Diagnostic criteria of neutropenia (ANC);</LI>
<LI>use of CSF in first cycle or after first neutropenia episode;</LI>
<LI>treatment schedule and CSF used;</LI>
<LI>CSF concurrent with chemotherapy or in intervals between cycles;</LI>
<LI>ANC median and mean in each arm at the beginning of study;</LI>
<LI>length of study.</LI>
</UL>
<P>We resolved disagreements by a consensus meeting. Where necessary we invited a third author to give an opinion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analysing and presenting the results</HEADING>
<P>We entered data regarding the endpoints of interest into Review Manager software (RevMan).<BR/>
<BR/>We performed a formal statistical analysis of heterogeneity using the Chi<SUP>2</SUP> test (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) and calculated the percentage of the variability in the effect estimates using I<SUP>2</SUP> as described by Higgins et al (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We set the statistical level of heterogeneity (Chi<SUP>2</SUP> P) at 0.10 and considered I<SUP>2 </SUP>below 30% to represent homogeneity. We assessed any identified heterogeneity in an effort to explain it. If we were unable to find an explanation we stressed such a finding in the review and highlighted that caution in the interpretation of these data was appropriate. Where we found that a cause for heterogeneity was apparent and justified a separate analysis of the studies with a particular characteristic, we undertook such analysis and presented it.</P>
<P>Where we found no heterogeneity, we included the studies in a meta-analysis for the outcomes selected above. We performed meta-analysis using RevMan 5.<BR/>
<BR/>For dichotomous data we calculated relative risk, odds ratio and Peto odds ratio (OR) (<LINK REF="REF-Yusuf-1985" TYPE="REFERENCE">Yusuf 1985</LINK>). If these data showed the same conclusion, we used Peto OR in the description of results. We set a significance level of 5% to test our hypothesis. We reported the 95% confidence interval (CI) in the statistical summary. When overall results were significant, we calculated the absolute risk reduction and the number needed to treat (NNT) or the number needed to harm (NNH) to produce or prevent an outcome based on the inverse of the absolute risk reduction (<LINK REF="REF-McQuay-1997" TYPE="REFERENCE">McQuay 1997</LINK>).</P>
<P>For continuous outcomes we used a fixed-effect method with the inverse variance approach. We calculated a weighted mean difference (WMD) when outcome measurements in all trials were made on the same scale. We used a standardised mean difference (SMD) when the trials all assessed the same outcome, but measured the outcome in a variety of ways. We did so irrespective of whether the data for each individual were single assessments or changed from baseline measures.</P>
<P>For purposes of count data, we calculated the logarithms of the rate ratios of each trial and combined them using the generic inverse variance method (<LINK REF="REF-Hasselblad-1995" TYPE="REFERENCE">Hasselblad 1995</LINK>) when a participant experienced an event more than once. We calculated an approximate standard error of the log rate ratio given by &#8730;(1/A + 1/C) whenever necessary.</P>
<P>We planned to assess the possibility of publication bias using the funnel plot method (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) for the primary endpoints.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Improving and updating reviews</HEADING>
<P>We will update every two years.</P>
</SUBSECTION>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-03-13 13:34:22 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently scanned more than 6800 citations identified in the computerised databases using the search strategy previously outlined. We identified 12 randomised controlled trials that met our inclusion criteria for full text reading and analysis of quality.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>Six studies (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>; <LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>; <LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>; <LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>; <LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>) met our inclusion criteria (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) and we included their data in the meta-analysis.</P>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of included studies</HEADING>
<P>Five trials described the effects of G-CSF (<LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>; <LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>; <LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>; <LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>). Only one trial studied the effects of GM-CSF (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>). There was a cross-over study (<LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>) where children were randomised to receive G-CSF starting four days after completion of either the first or the second block of intensification therapy. In order to avoid the carry-over situation that interferes with the effects of the intervention, we decided to include available data of the first period. We found only one kind of data extractable for meta-analysis from this trial: delay of chemotherapy.<BR/>One trial defined neutropenia as absolute neutrophil count (ANC) of less than 1000/mm<SUP>3</SUP> (<LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>) while the other five considered neutropenia an ANC of less than 500/mm<SUP>3</SUP>. One study (<LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>) included one participant with advanced T-cell Hodgkin's lymphoma who underwent a treatment protocol similar to patients with ALL and was therefore considered eligible for the trial.<BR/>
<BR/>Two of the included studies evaluated some outcomes after only one cycle of treatment (<LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>; <LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>). Welte et al (<LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>) evaluated outcomes coming from observation after nine courses of chemotherapy, while Michel (<LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>) analysed six courses, Dibenedetto (<LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>) studied three cycles and Calderwood (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>) analysed data after two courses of chemotherapy.<BR/>
<BR/>Three studies used 5 mcg/kg body weight per day (<LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>; <LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>) while two others (<LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>; <LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>) used 10 mcg/kg body weight per day of G-CSF. GM-CSF was used at a dose of 5.5 mcg/kg on days 5 to 11 and 19 to 25 of each treatment cycle (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>).<BR/>
<BR/>Most of the included studies used CSF as primary prophylaxis and only one (<LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>) used CSF as secondary prophylaxis. The objective of treatment is to prevent subsequent episodes of febrile neutropenia.<BR/>
<BR/>We retrieved no eligible citations from either the search of databases of ongoing trials or contact with the pharmaceuticals companies.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>Six studies did not meet the inclusion criteria. The reasons for exclusion were: involvement of adult participants; data non-extractable for children; and non-randomised design (<LINK REF="STD-Chen-1998" TYPE="STUDY">Chen 1998</LINK>; <LINK REF="STD-Heath-2003" TYPE="STUDY">Heath 2003</LINK>; <LINK REF="STD-Laver-1998" TYPE="STUDY">Laver 1998</LINK>; <LINK REF="STD-Little-2002" TYPE="STUDY">Little 2002</LINK>; <LINK REF="STD-Ohno-1993" TYPE="STUDY">Ohno 1993</LINK>; <LINK REF="STD-Saarinen_x002d_Pihkala2000" TYPE="STUDY">Saarinen-Pihkala2000</LINK>) (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>Calderwood et al and Welte et al (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>) described an adequate method of randomisation but only one (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>) had a clear and adequate allocation concealment. Although <LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK> had described adequate randomisation, the two arms of comparison were unbalanced: there were more children with a specific cytogenetic feature (t(4;11)) in the non-G-CSF group than in the G-CSF group (six patients versus one patient, respectively; P = 0.05). This difference explained the higher mean white blood cell count at diagnosis in the non-G-CSF group (223 x 10<SUP>9</SUP> versus 136 x 10<SUP>9</SUP>/L, respectively) and the higher incidence of infants less than one year old in the same group (six patients versus one patient respectively).<BR/>
<BR/>Four studies (<LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>; <LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>; <LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>) used no treatment in the control group. Two other trials (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>; <LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>) used a placebo in the group which was also double blind.<BR/>
<BR/>There was a variation in CSF doses used. <LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK> used 5.5 mcg/kg body weight per day of GM-CSF in his trial. Three studies used 5 mcg/kg body weight per day of G-CSF (<LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>; <LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>) while two others (<LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>; <LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>) used 10 mcg/kg body weight per day.<BR/>
<BR/>Alpha-error and beta-error were pre-determined in two trials (<LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>) but the number of participants was not reached in one of them (<LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>). Intention-to-treat analysis was performed in only two of the included studies (<LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>).<BR/>
<BR/>Only one trial included in the meta-analysis was referred to as multicentre (<LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-03-13 13:34:22 +0100" MODIFIED_BY="[Empty name]">
<P>Our analysis included results of six trials (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>; <LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>; <LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>; <LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>; <LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>) with a total of 333 participants. One hundred and sixty-two children with ALL were randomised to use CSF as the treatment group and 171 were allocated to the control group (placebo or no treatment).</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary end points</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Number of febrile neutropenia episodes</HEADING>
<P>Febrile neutropenia was defined (<LINK REF="REF-Ozer-2000" TYPE="REFERENCE">Ozer 2000</LINK>) as oral temperature above 38.3ºC unrelated to transfusions associated with grade IV neutropenia (ANC less than 500/mm<SUP>3</SUP>). Only two studies comprising 451 cycles of treatment had extractable data about febrile neutropenia episodes (<LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>). There were 68 episodes of febrile neutropenia in 226 cycles of chemotherapy in the CSF group and 112 episodes in 228 cycles of treatment in the control group. We considered that each participant could experience an episode of febrile neutropenia episode and may also experience it more than once. For this reason we calculated the logarithms of the rate ratios in each trial to perform meta-analysis (<LINK REF="REF-Hasselblad-1995" TYPE="REFERENCE">Hasselblad 1995</LINK>). Meta-analysis showed significant difference to the CSF group (Rate Ratio 0.63, 95% Confidence Interval (CI) 0.46 to 0.85, <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We detected substantial statistical heterogeneity between the studies (x<SUP>2</SUP> = 4.80, degrees of freedom (df): 1; P = 0.03). There was 47% of risk reduction (Risk Reduction -0.47, 95% CI -0.77 to -0,16) with a number needed to treat (NNT) of 2 to prevent a febrile neutropenia episode. A funnel plot was not generated because only two studies were included in the analyses and publication bias could not be assessed in this case (Table 1).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Death</HEADING>
<P>Only two studies (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>; <LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>) described overall mortality rate with a small number of deaths or no deaths occurring during the trial period. Calderwood reported one death due to septic shock, and Michel described three deaths from therapy-related toxicity.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary end points</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Time to neutrophil count recovery</HEADING>
<P>We considered the number of days needed to rise from an ANC less than 500/mm<SUP>3</SUP> after each chemotherapy course with or without CSF. Three studies (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>; <LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>; <LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>) with 134 participants had extractable data related to the length of neutropenia episode. Patients receiving CSF had shorter duration of neutropenia compared to patients not receiving CSF (WMD = -3.44, 95% CI -4.76 to -2.12, P &lt; 0.00001, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) but we detected a small heterogeneity between studies (x<SUP>2</SUP> = 5.22, df: 2, P = 0.07). The data from <LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK> was the main cause of this heterogeneity and we performed the analysis of data excluding this study (<LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>).<BR/>
<BR/>With two studies (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>; <LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>) including 67 participants, the group using CSF did not show shorter duration of neutropenia compared to the group not receiving CSF (WMD = -1.11, 95% CI -3.55 to 1.32, P = 0.37, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). We resolved the heterogeneity detected between studies after exclusion of the data from Michel et al (x<SUP>2</SUP> = 0.28, df: 1; P = 0.60).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incidence and length of hospitalisation</HEADING>
<P>We considered the number of episodes and days of hospitalisation due to chemotherapy infusions or any complication and pooled them. There were no extractable data about the incidence of hospitalisation in the included trials. In the evaluation of the length of hospitalisation, meta-analysis of three trials (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>; <LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>; <LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>) including 134 participants showed significant benefit of CSF addition to the chemotherapy compared to control groups (WMD = -1.58, 95% CI -3.00 to -0.15; P = 0.03, <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). There was no evidence of heterogeneity between the studies (x<SUP>2</SUP> = 0.71, df: 2; P = 0.70).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of infectious diseases episodes</HEADING>
<P>We considered every objective sign of infection of any site confirmed by microbiologic assay or radiologic exam associated with compatible clinical signs in the groups studied. Five studies (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>; <LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>; <LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>; <LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>) had data of 958 cycles of treatment which we included in meta-analysis. There were 45 episodes of infection among 476 cycles of chemotherapy in the CSF group and 91 episodes in 482 cycles of treatment in the control group. Meta-analysis showed a significant reduction in the incidence of infection (Rate Ratio=0.56, 95% CI 0.39 to 0.80, P = 0.002, <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>) without detectable statistical heterogeneity (x<SUP>2</SUP> = 4.91; df: 4; P = 0.30). There was a 58% of risk difference (RD -0.58, 95% CI -0.93 to -0.22) with a NNT of 2 to prevent an infectious disease episode.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incidence and length of delays in chemotherapy courses</HEADING>
<P>We considered any delay to restart the subsequent course of chemotherapy as an episode. Four studies (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>; <LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>; <LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>) including 118 patients had data related to delays in chemotherapy courses extractable for meta-analysis. There were 30 delay episodes among 257 cycles of therapy in CSF groups compared to 46 delays in 281 cycles among control patients. The analysis did not show a difference between groups (Rate Ratio = 0.75, 95% CI 0.47 to 1.20, P = 0.23, <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). There was no detectable heterogeneity in this analysis (x<SUP>2</SUP> = 1,24; df: 3; P = 0.74).<BR/>
<BR/>The trials did not report on the duration of delays and meta-analysis of this outcome was not feasible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Side effects</HEADING>
<P>A lack of uniformity of adverse effects described between trials meant that we could not perform meta-analysis. Overall we considered the adverse effects associated with the use of CSF in children to be mild. Calderwood detected that 15% of patients had localised redness or swelling at injection sites, low-grade fever or muscle aches and pains. One patient in this study experienced an urticarial eruption which necessitated the patient's withdrawal from the study (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>). In the trial coordinated by Welte et al the authors described one adverse event (vasculitis of WHO grade III) that was related to the administration of G-CSF (<LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>). Dibenedetto reported that G-CSF was well tolerated with mild bone tenderness as the only side effect being observed in two patients (<LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>).<BR/>
<BR/>Data about the use of antibiotics were presented in three trials (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>; <LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>). Of these, two (<LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>) presented median values with insufficient data to calculate mean values for meta-analysis. Calderwood et al reported no significant difference between the experimental and control groups in the number of days that patients needed antibiotics (P = 0.73) (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Relapse</HEADING>
<P>None of the included studies was long enough to verify a relapse rate and there were no data available. Therefore we could not perform meta-analysis of this important outcome.</P>
<P>Additional information is shown in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> and <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>Colony-stimulating factors are being used to prevent febrile neutropenia and infection in patients undergoing myelosuppressive treatment for cancer. Their use is more established in adult populations where CSF is often used in cancer treatment. Some systematic reviews had already evaluated the effect of CSF in chemotherapy-induced febrile neutropenia in cancer (<LINK REF="REF-Clark-2005" TYPE="REFERENCE">Clark 2005</LINK>) and more particularly in malignant lymphoma (<LINK REF="REF-Bohlius-2008" TYPE="REFERENCE">Bohlius 2008</LINK>). Meanwhile the effect of CSF in febrile neutropenia due to chemotherapy in childhood cancer remains unclear and inspired this review.<BR/>
<BR/>This systematic review presents evidence for the use of CSF to prevent febrile neutropenia in children with ALL during chemotherapy. There is still only a small number of RCTs involving paediatric subjects and most of them present methodological quality concerns.<BR/>
<BR/>A Paediatric Oncology Group trial found contradictions between guidelines and clinical practices about CSF use in the paediatric oncology field (<LINK REF="REF-Parsons-2000" TYPE="REFERENCE">Parsons 2000</LINK>). In the absence of definitive data, paediatric oncologists adopt therapeutic patterns based on convenience. Once established, such patterns are difficult to transform.<BR/>
<BR/>In 1997, the US Food and Drug Administration Modernization Act showed the need for specific RCTs in paediatric populations to define the benefits of various medications. Because of the development of new therapeutic agents, their effects should be determined through well-designed RCTs and determination of relevant outcomes. In the absence of this information, recommendations incorporate evidence derived from trials in adult populations (<LINK REF="REF-Ozer-2000" TYPE="REFERENCE">Ozer 2000</LINK>; <LINK REF="REF-Schaison--1998" TYPE="REFERENCE">Schaison 1998</LINK>). In addition, the opinions of paediatric oncologists have been influencing routine use of CSF. There is still a need for further, well-designed RCTs in this field.<BR/>
<BR/>We made important observations relating to some aspects of the included studies in this systematic review. First, there is no consensus about the ideal dose of CSF for children. Three studies used 5 mcg/kg body weight per day (<LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>; <LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>) while two others (<LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>; <LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>) used double this dose. We tried to perform a subgroup analysis comparing two different doses but, because of the small number of included studies, this was a meaningless exercise. The dearth of RCTs to determine the ideal doses of CSF to children may lead to a waste of financial resources and unnecessary exposure of paediatric participants to potential side effects without any clear conclusion. This review showed the need for new trials to determine the ideal doses of CSF for children.<BR/>
<BR/>Second, most of the studies included were of short duration of evaluation periods. Welte et al (<LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>) evaluated outcomes coming from observation after nine courses of chemotherapy, while Michel (<LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>) analysed six courses, Dibenedetto (<LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>) analysed data from three cycles and Calderwood (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>) analysed data after two courses of chemotherapy. The others (<LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>; <LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>) evaluated some outcomes after only one cycle of treatment. Such a short period of study can influence the result of this systematic review. Long-term treatment required in ALL chemotherapy regimes often diminishes bone marrow reserves progressively. This can negate the potential benefit of CSF after a low reserve is reached. Regardless of the treatment protocol used, the use of CSF as primary or secondary prophylaxis should comprise the most myelosuppressive phases in ALL treatment that include induction, intensification and re-intensification phases. These phases have higher prevalence of febrile neutropenia and other complications of chemotherapy than the maintenance phase. Depending on each treatment protocol, the duration of each phase could vary considerably. To evaluate outcomes such as mortality, relapse and response rates, a long-term follow up of at least five years would be necessary. Such long follow ups could easily be achieved since most paediatric oncology centres do follow most of the patients for more than five years.<BR/>
<BR/>In addition, the safety of CSF after long-term use still needs to be determined. Inukai et al described the finding of receptors to G-CSF, GM-CSF and IL-3 (<LINK REF="REF-Inukai-1998" TYPE="REFERENCE">Inukai 1998</LINK>) on the membrane of leukaemic lymphoblasts. Some initial molecular studies found growth of ALL blast cell colonies after exposure to G-CSF(<LINK REF="REF-Benko-2001" TYPE="REFERENCE">Benko 2001</LINK>), GM-CSF and other cytokines (p. ex interleukin)(<LINK REF="REF-Gattei-1997" TYPE="REFERENCE">Gattei 1997</LINK>) in in vitro assay. To verify the possibility of clinical consequences of these findings, well-designed RCTs with long-term follow up are needed to evaluate if frequent use of CSF during myelosuppressive therapy can influence the prognosis of ALL regarding response, relapse and overall mortality rates. Considering that most ALL chemotherapy regimens are highly intense and toxic to the bone marrow from the outset, it would be necessary to have studies with prophylactic use of CSF during entire intensive phases of chemotherapy and long-term follow-up to determine the most important outcomes regarding effectiveness and safety.<BR/>
<BR/>It is also useful to discuss some characteristics of the design of the included studies. Clark et al performed a cross-over trial (<LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>) which is known to be subject to potential risk of bias, particularly the 'carry-over' effect that would underestimate the overall effect. To reduce the risk of bias, we used the common strategy of focusing the analysis on the first period only. Additionally, only one trial described a clear and adequate allocation concealment (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>), which is an important measure to prevent bias. Another study had different baseline characteristics between the treatment and control groups; this is the result of inadequate randomisation. In the study by Michel et al, more children with t(4;11) cytogenetic feature, with consequent higher mean white blood cell counts and a higher incidence of infants less than one year old were randomised to the non-G-CSF group (<LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>). Another factor which has an impact on the quality of studies is the pharmaceutical company funding of three RCTs (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>; <LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>). Pharmaceutical company funding is empirically linked to potential bias (<LINK REF="REF-Egger-2001" TYPE="REFERENCE">Egger 2001</LINK>), although many developed and developing countries still depend on this source of funding to promote research (<LINK REF="REF-Montaner-2001" TYPE="REFERENCE">Montaner 2001</LINK>). There is a need to avoid pharmaceutical funding as much as possible to minimise results bias and publication bias (<LINK REF="REF-Lechxin-2003" TYPE="REFERENCE">Lechxin 2003</LINK>).<BR/>
<BR/>The meta-analysis of data derived from two RCTs (<LINK REF="STD-Pui-1997" TYPE="STUDY">Pui 1997</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>) showed statistical difference in favour of CSF use to prevent febrile neutropenia in children undergoing ALL treatment. Substantial heterogeneity was also detected through the chi<SUP>2</SUP> test (P = 0.03). We also found this to be the case when we quantified inconsistency across studies (I<SUP>2</SUP> = 79%). The results of this analysis should therefore be interpreted with caution and not considered definitive. The inclusion of data from other RCTs could reduce the statistical heterogeneity between the trials and confirm these results. There is a clear consensus among specialists that the major intention of the use of CSF is the prevention of febrile neutropenia. However, most of the included studies did not evaluate or report adequately on this important outcome.<BR/>
<BR/>Another important purpose of the addition of CSF to chemotherapy of paediatric ALL would be a reduction in the duration of neutropenia. The meta-analysis of three studies (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>; <LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>; <LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>) showed that the length of episodes of neutropenia could be reduced by CSF use but this is mainly due to a heterogeneity coming from <LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>. As we analysed the quality of this trial, we found that the comparison groups were unbalanced and considered this the cause of the heterogeneity we detected. After analysis excluding Michel et al, both heterogeneity and the effect of reducing the duration of neutropenia disappeared.<BR/>
<BR/>On average the use of CSF reduced the length of hospital stay significantly by one day (mean of five days in the CSF group versus six days in the control group). To judge the economic impact of the results, a cost-effectiveness analysis separated for different economic environments would be necessary (<LINK REF="REF-Elting-2002" TYPE="REFERENCE">Elting 2002</LINK>). ALL treatment leads to high frequency and prolonged hospitalisation (<LINK REF="REF-Aquino-1997" TYPE="REFERENCE">Aquino 1997</LINK>; <LINK REF="REF-Bash-1994" TYPE="REFERENCE">Bash 1994</LINK>; <LINK REF="STD-Welte-1996" TYPE="STUDY">Welte 1996</LINK>) and a one-day reduction in hospitalisation may be of no consequence when it comes to cost and quality of life.<BR/>
<BR/>When a subsequent chemotherapy course starts after the scheduled day due to complications from treatment, we defined this as a delay. We assessed a possible difference in the results by the fact that this meta-analysis included data from one study (<LINK REF="STD-Clarke-1999" TYPE="STUDY">Clarke 1999</LINK>) that defined neutropenia as an ANC of less than 1000/mm<SUP>3</SUP>, while the others considered neutropenia to be an ANC of less than 500/mm<SUP>3</SUP>. This was the only outcome available from Clarke et al for this systematic review. The small number of participants and the statistical homogeneity found between trials (I<SUP>2</SUP>=0%) prompted us to consider the inclusion of this trial in the analysis even though the definition of neutropenia was different.<BR/>
<BR/>Chemotherapy regimens based on multiple drugs are often administered with the aim of enhancing dose intensity (<LINK REF="STD-Michel-2000" TYPE="STUDY">Michel 2000</LINK>). Delays in the administration of scheduled chemotherapy may reduce the overall dose intensity which in turn may compromise long-term results (<LINK REF="REF-Pui-2001" TYPE="REFERENCE">Pui 2001</LINK>). In this review, the meta-analysis of four trials showed that there is no evidence that the addition of CSF in chemotherapy regimens in ALL diminishes treatment delay. However, the short duration of studies makes the long-term effect uncertain.<BR/>
<BR/>In the present review the addition of CSF after chemotherapy courses significantly reduced episodes of infections in the group treated with CSF (Rate Ratio = 0.56, 95% CI 0.39 to 0.80, P = 0.002). As with the febrile neutropenia episodes outcome, we applied some indirect calculation to evaluate the total cycles of chemotherapy in each arm. The result must therefore be interpreted with caution. As severe neutropenia with concomitant infection is life-threatening, the evidence of a lower rate of infection with the use of CSF raises hopes of a reduction in overall mortality rates. Only studies designed with long-term follow up will allow such evaluation. In addition, infection leads to long hospital stays, use of broad-spectrum antibiotics, laboratory and radiologic exams and consequently, higher treatment costs. High-quality studies in the future could provide data for cost effectiveness studies.<BR/>
<BR/>A primary endpoint of this systematic review was death (mortality). However, it was not possible to combine the data in a meta-analysis. Because of the short follow-up times in the studies analysed in this review, the mortality was low as discussed above. Longer follow-up periods could determine differences in remission, relapse and mortality rates.<BR/>
<BR/>Adverse effects of CSF use seem to be more frequent and severe in adult populations (<LINK REF="REF-Biesma-1990" TYPE="REFERENCE">Biesma 1990</LINK>; <LINK REF="REF-Garcia_x002d_Carbonero-2001" TYPE="REFERENCE">Garcia-Carbonero 2001</LINK>; <LINK REF="REF-Maher-1994" TYPE="REFERENCE">Maher 1994</LINK>; <LINK REF="REF-Mayordomo-1995" TYPE="REFERENCE">Mayordomo 1995</LINK>; <LINK REF="REF-Riikonen-1994" TYPE="REFERENCE">Riikonen 1994</LINK>). RCTs in paediatric populations do not demonstrate great concern about adverse effects of CSF administration. Safety could be better determined after longer follow up and administration of CSF in future RCTs.<BR/>
<BR/>The small number of included studies and great differences in the reporting of results between them prevented more meaningful subgroup analysis. We did not perform subgroup analysis comparing G-CSF and GM-CSF as only one included study evaluated GM-CSF (<LINK REF="STD-Calderwood-1994" TYPE="STUDY">Calderwood 1994</LINK>). Even though some RCTs do not show differences in effectiveness and safety between G-CSF and GM-CSF in various clinical situations (<LINK REF="REF-Alvarado-1999" TYPE="REFERENCE">Alvarado 1999</LINK>; <LINK REF="REF-Beveridge-1998" TYPE="REFERENCE">Beveridge 1998</LINK>), some others report that G-CSF has greater benefit compared to GM-CSF (<LINK REF="REF-Palmeri-1999" TYPE="REFERENCE">Palmeri 1999</LINK>; <LINK REF="REF-Pierelli-2001" TYPE="REFERENCE">Pierelli 2001</LINK> <LINK REF="REF-Weaver-2001" TYPE="REFERENCE">Weaver 2001</LINK>). This could explain the widespread tendency to use G-CSF in clinical practice and research.<BR/>
<BR/>Another subgroup we considered is that of primary and secondary prophylaxis studies. Dibenedetto et al (<LINK REF="STD-Dibenedetto-1995" TYPE="STUDY">Dibenedetto 1995</LINK>) was the only included study that used CSF as secondary prevention. We analysed data from this study for most of the outcomes and identified no heterogeneity. It would be interesting to see if new RCTs evaluating the use of CSF as secondary prophylaxis are planned, as this approach could lead to different outcomes.<BR/>
<BR/>The empirical doses of 5 mcg/kg body weight per day or 10 mcg/kg body weight per day of G-CSF used in the included studies warrant additional studies. Different doses could have a bearing on all outcomes evaluated in the studies, particularly if the optimal dose is yet to be found. The importance of trials to establish the optimal dose of CSF in children cannot be overstated.<BR/>
<BR/>Currently there is no evidence to support the routine use of CSF in children with ALL undergoing myelosuppressive chemotherapy. In developing countries, where medication costs are greater than hospitalisation costs, the routine use of CSF may not financially viable (<LINK REF="REF-Bennett-2000" TYPE="REFERENCE">Bennett 2000</LINK>; <LINK REF="REF-Elting-2002" TYPE="REFERENCE">Elting 2002</LINK>).<BR/>
<BR/>This systematic review is based on short-duration RCTs without consensus about CSF dose in children. Future RCTs should focus on long-term follow up and determination of ideal CSF dosage in order to evaluate the real role of CSF to prevent febrile neutropenia and improve outcomes in paediatric patients with ALL.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>There is evidence that the prophylactic administration of CSF reduces length of hospitalisation and rate of infection during treatment. There is no evidence that the use of CSF reduces the length of neutropenia episodes or diminishes delay of chemotherapy courses in paediatric patients with ALL undergoing myelosuppressive chemotherapy. Although there were statistically significant fewer febrile neutropenia episodes in the CSF group, substantial heterogeneity between trials prevents us from drawing conclusions, and no useful information is available on survival.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>Future RCTs should focus on determination of optimal CSF dosage as well as the use of CSF during all cycles of the most intensive phases of treatment and long-term follow up in order to determine its real role in the prevention of febrile neutropenia in paediatric patients with ALL undergoing myelosuppressive chemotherapy. There must be an effort to conduct high-quality trials with proper evaluation and reporting of the main outcomes including mortality. Cost-effectiveness analysis of the implication of routine use of CSF in ALL therapy should be performed with consideration of different economic scenarios.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>We are grateful to the editors of the Cochrane Haematological Malignancies Group, specially Dr. Nicole Skoetz for her important contributions in the process of updating the review. We also want to thank Durhane Wong-Rieger for the valuable comments from a consumer perspective.</P>
<P>
<BR/>We want to acknowledge in particular Dr. Sue Richards' crucial help in data extraction and analysis, which made possible the main results in this review.<BR/>
<BR/>And we also want to thank Laura Mellor for her important editing support.</P>
<P>The editorial base of the Cochrane Haematological Malignancies Group is funded by the German Ministry of Education and Research (BMBF).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-05-13 08:58:36 +0200" MODIFIED_BY="Nicole Skoetz">
<UL>
<LI>ECS wrote the protocol and performed the search for articles, selected articles, extracted and analysed data and wrote the manuscript.</LI>
<LI>OC contributed to the protocol elaboration, performed the manual search for articles, selected articles, extracted and analysed data.</LI>
<LI>ADS contributed to the protocol elaboration, performed the manual search for articles, selected articles, extracted and analysed data and also served as a third opinion to solve disagreements.</LI>
<LI>SRB conceptualised the study and contributed to the protocol elaboration. She contacted the authors of selected articles and wrote the manuscript.</LI>
<LI>SR extracted and analysed data and amended the review text.</LI>
</UL>
<P>All authors contributed to the analysis and interpretation of data and results.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-02-12 16:27:04 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-02-12 16:16:35 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-02-12 16:13:52 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Calderwood-1994" MODIFIED="2009-02-12 16:12:16 +0100" MODIFIED_BY="[Empty name]" NAME="Calderwood 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-02-12 16:12:16 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;41.Calderwood S, Romeyer F, Blanchette V, Chan H, Doyle J, Greenberg M, et al. Concurrent RhGM-CSF does not offset myelosuppression from intensive chemotherapy: randomized placebo-controlled study in childhood acute lymphoblastic leukemia. Am J Hematol 1994;47(1):27-32.&lt;/p&gt;" NOTES_MODIFIED="2009-02-12 16:12:16 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calderwood S, Romeyer F, Blanchette V, Chan H, Doyle J, Greenberg M et al</AU>
<TI>Concurrent RhGM-CSF does not offset myelosuppression from intensive chemotherapy: randomized placebo-controlled study in childhood acute lymphoblastic leukemia</TI>
<SO>American Journal of Hematology</SO>
<YR>1994</YR>
<VL>47</VL>
<NO>1</NO>
<PG>27-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-1999" MODIFIED="2009-02-12 16:12:54 +0100" MODIFIED_BY="[Empty name]" NAME="Clarke 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-02-12 16:12:54 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;38.Clarke V, Dunstan FD, Webb DK. Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia. Med Pediatr Oncol 1999;32(5):331-5.&lt;/p&gt;" NOTES_MODIFIED="2009-02-12 16:12:54 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke V, Dunstan FD, Webb DK</AU>
<TI>Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia</TI>
<SO>Medical Pediatric Oncology</SO>
<YR>1999</YR>
<VL>32</VL>
<NO>5</NO>
<PG>331-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dibenedetto-1995" MODIFIED="2009-02-12 16:13:10 +0100" MODIFIED_BY="[Empty name]" NAME="Dibenedetto 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-02-12 16:13:10 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;36.Dibenedetto SP, Ragusa R, Ippolito AM, Lo Nigro L, Di Cataldo A, D'Amico S, et al. Assessment of the value of treatment with granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a randomized clinical trial. Eur J Haematol 1995;55(2):93-6.&lt;/p&gt;" NOTES_MODIFIED="2009-02-12 16:13:10 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dibenedetto SP, Ragusa R, Ippolito AM, Lo Nigro L, Di Cataldo A, D'Amico S et al</AU>
<TI>Assessment of the value of treatment with granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a randomized clinical trial</TI>
<SO>European Journal of Haematology</SO>
<YR>1995</YR>
<VL>55</VL>
<NO>2</NO>
<PG>93-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michel-2000" MODIFIED="2009-02-12 16:13:23 +0100" MODIFIED_BY="[Empty name]" NAME="Michel 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-02-12 16:13:23 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;22.Michel G, Landman-Parker J, Auclerc MF, Mathey C, Leblanc T, Legall E, et al. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. J Clin Oncol 2000;18(7):1517-24.&lt;/p&gt;" NOTES_MODIFIED="2009-02-12 16:13:23 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michel G, Landman-Parker J, Auclerc MF, Mathey C, Leblanc T, Legall E et al</AU>
<TI>Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>7</NO>
<PG>1517-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pui-1997" MODIFIED="2009-02-12 16:13:37 +0100" MODIFIED_BY="[Empty name]" NAME="Pui 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-02-12 16:13:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;12.Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997;336(25):1781-7.&lt;/p&gt;" NOTES_MODIFIED="2009-02-12 16:13:37 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT et al</AU>
<TI>Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>336</VL>
<NO>25</NO>
<PG>1781-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Welte-1996" MODIFIED="2009-02-12 16:13:52 +0100" MODIFIED_BY="[Empty name]" NAME="Welte 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-02-12 16:13:52 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;2.Welte K, Reiter A, Mempel K, Pfetsch M, Schwab G, Schrappe M, et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group. Blood 1996;87(8):3143-50.&lt;/p&gt;" NOTES_MODIFIED="2009-02-12 16:13:52 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Welte K, Reiter A, Mempel K, Pfetsch M, Schwab G, Schrappe M et al</AU>
<TI>A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group</TI>
<SO>Blood</SO>
<YR>1996</YR>
<VL>87</VL>
<NO>8</NO>
<PG>3143-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-02-12 16:16:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1998" MODIFIED="2009-02-12 16:14:00 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-02-12 16:14:00 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;39.Chen SH, Liang DC, Liu HC. High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia. Am J Hematol 1998;58(1):20-3.&lt;/p&gt;" NOTES_MODIFIED="2009-02-12 16:14:00 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen SH, Liang DC, Liu HC</AU>
<TI>High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia</TI>
<SO>American Journal of Hematology</SO>
<YR>1998</YR>
<VL>58</VL>
<NO>1</NO>
<PG>20-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heath-2003" MODIFIED="2009-02-12 16:14:57 +0100" MODIFIED_BY="[Empty name]" NAME="Heath 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-02-12 16:14:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heath JA, Steinherz PG, Altman A, Sather H, Jhanwar S, Halpern S et al</AU>
<TI>Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: A Children's Cancer Group Study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>1612-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laver-1998" MODIFIED="2009-02-12 16:15:21 +0100" MODIFIED_BY="[Empty name]" NAME="Laver 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-02-12 16:15:21 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;29.Laver J, Amylon M, Desai S, Link M, Schwenn M, Mahmoud H, et al. Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study. J Clin Oncol 1998;16(2):522-6.&lt;/p&gt;" NOTES_MODIFIED="2009-02-12 16:15:21 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laver J, Amylon M, Desai S, Link M, Schwenn M, Mahmoud H et al</AU>
<TI>Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>2</NO>
<PG>522-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Little-2002" MODIFIED="2009-02-12 16:15:45 +0100" MODIFIED_BY="[Empty name]" NAME="Little 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-02-12 16:15:45 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;26.Little MA, Morland B, Chisholm J, Hole A, Shankar A, Devine T, et al. A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Med Pediatr Oncol 2002;38(2):98-103.&lt;/p&gt;" NOTES_MODIFIED="2009-02-12 16:15:45 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Little MA, Morland B, Chisholm J, Hole A, Shankar A, Devine T et al</AU>
<TI>A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL</TI>
<SO>Medical Pediatric Oncology</SO>
<YR>2002</YR>
<VL>38</VL>
<NO>2</NO>
<PG>98-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohno-1993" MODIFIED="2009-02-12 16:16:13 +0100" MODIFIED_BY="[Empty name]" NAME="Ohno 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-02-12 16:16:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohno R, Tomonaga M, Oshima T, Masaoka T, Asou N, Oh H et al</AU>
<TI>A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. Japan Adult Leukemia Study Group</TI>
<SO>International Journal of Hematology</SO>
<YR>1993</YR>
<VL>58</VL>
<PG>73-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saarinen_x002d_Pihkala2000" MODIFIED="2009-02-12 16:16:35 +0100" MODIFIED_BY="[Empty name]" NAME="Saarinen-Pihkala2000" YEAR="2000">
<REFERENCE MODIFIED="2009-02-12 16:16:35 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;6.Saarinen-Pihkala UM, Lanning M, Perkkio M, Makipernaa A, Salmi TT, Hovi L, et al. Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children. Med Pediatr Oncol 2000;34(5):319-27.&lt;/p&gt;" NOTES_MODIFIED="2009-02-12 16:16:35 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saarinen-Pihkala UM, Lanning M, Perkkio M, Makipernaa A, Salmi TT, Hovi L et al</AU>
<TI>Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children</TI>
<SO>Medical Pediatric Oncology</SO>
<YR>2000</YR>
<VL>34</VL>
<NO>5</NO>
<PG>319-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-02-12 16:27:04 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-02-12 16:27:04 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alexander-1999" MODIFIED="2009-02-12 16:16:50 +0100" MODIFIED_BY="[Empty name]" NAME="Alexander 1999" TYPE="JOURNAL_ARTICLE">
<AU>Alexander SW, Pizzo PA</AU>
<TI>Current considerations in the management of fever and neutropenia</TI>
<SO>Current Clinical Topics of Infectious Diseases</SO>
<YR>1999</YR>
<VL>19</VL>
<PG>160-80</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:36:26 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Alvarado-1999" MODIFIED="2009-02-12 16:17:00 +0100" MODIFIED_BY="[Empty name]" NAME="Alvarado 1999" TYPE="JOURNAL_ARTICLE">
<AU>Alvarado Ibarra ML, Borbolla Escoboza JR, Lopez-Hernandez MA, Gonzalez-Avante CM, FloresChapa JD, Trueba Christy E et al</AU>
<TI>Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF</TI>
<SO>Revista de Investigacion Clinica</SO>
<YR>1999</YR>
<VL>2</VL>
<PG>77-80</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:36:41 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Aquino-1997" MODIFIED="2009-02-12 16:17:17 +0100" MODIFIED_BY="[Empty name]" NAME="Aquino 1997" TYPE="JOURNAL_ARTICLE">
<AU>Aquino VM, Tkaczewski I, Buchanan GR</AU>
<TI>Early discharge of low-risk febrile neutropenic children and adolescents with cancer</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>1</NO>
<PG>74-8</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:37:22 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Armitage-1998" MODIFIED="2009-01-22 15:47:52 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Armitage 1998" TYPE="JOURNAL_ARTICLE">
<AU>Armitage JO</AU>
<TI>Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor</TI>
<SO>Blood</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>12</NO>
<PG>4491-508</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:37:40 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Bash-1994" MODIFIED="2009-01-22 15:47:45 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Bash 1994" TYPE="JOURNAL_ARTICLE">
<AU>Bash RO, Katz JA, Cash JV, Buchanan GR10</AU>
<TI>Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia</TI>
<SO>Cancer</SO>
<YR>1994</YR>
<VL>74</VL>
<NO>1</NO>
<PG>189-96</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:47:45 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Benko-2001" MODIFIED="2009-02-12 16:17:35 +0100" MODIFIED_BY="[Empty name]" NAME="Benko 2001" TYPE="JOURNAL_ARTICLE">
<AU>Benki I, Kovacs P, Szegedi I, Megyeri A, Kiss A, Balogh E et al</AU>
<TI>Effect of myelopoieetic and pleiotropic cytokines on colony formation by bast cells of children with acute lymphoblastic leukemia</TI>
<SO>Naunyn-Schmiedeberg's Archives of Pharmacology</SO>
<YR>2001</YR>
<VL>363</VL>
<NO>5</NO>
<PG>499-508</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11383710"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bennett-2000" MODIFIED="2009-02-12 16:17:51 +0100" MODIFIED_BY="[Empty name]" NAME="Bennett 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bennett CL, Stinson TJ, Lane D, Amylon M, Land VJ, Laver JH</AU>
<TI>Cost analysis of filgrastim for prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials</TI>
<SO>Medical Pediatric Oncology</SO>
<YR>2000</YR>
<VL>34</VL>
<PG>92-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beveridge-1998" MODIFIED="2009-02-12 16:18:07 +0100" MODIFIED_BY="[Empty name]" NAME="Beveridge 1998" TYPE="JOURNAL_ARTICLE">
<AU>Beveridge RA, Miller JA, Kales AN, Binder RA, Robert NJ, Harvey JH et al</AU>
<TI>A comparison of efficacy of sargramostin (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression</TI>
<SO>Cancer Investigation</SO>
<YR>1998</YR>
<VL>6</VL>
<PG>366-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9679526"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Biesma-1990" MODIFIED="2009-02-12 16:18:36 +0100" MODIFIED_BY="[Empty name]" NAME="Biesma 1990" TYPE="JOURNAL_ARTICLE">
<AU>Biesma B, De Vries EG, Willemse PH, Sluiter WJ, Postmus PE, Limburg PC et al</AU>
<TI>Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever</TI>
<SO>European Journal of Cancer</SO>
<YR>1990</YR>
<VL>26</VL>
<PG>932-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bohlius-2008" MODIFIED="2008-10-23 14:49:57 +0200" MODIFIED_BY="[Empty name]" NAME="Bohlius 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A.</AU>
<TI>Granulopoiesis-stimulating factor to prevent adverse effects in the treatment of malignant lymphoma.</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-10-23 14:49:57 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-23 14:49:57 +0200" MODIFIED_BY="[Empty name]" OTHERTYPE="CD" TYPE="OTHER" VALUE="003189.pub4"/>
<IDENTIFIER MODIFIED="2008-10-23 14:49:17 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651850"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Burdach-1995" MODIFIED="2009-01-22 15:46:59 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Burdach 1995" TYPE="JOURNAL_ARTICLE">
<AU>Burdach SE, Muschenich M, Josephs W, Frisch J, Schulz G, Jurgens H, et al</AU>
<TI>Granulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Results of a prospective randomized study</TI>
<SO>Cancer</SO>
<YR>1995</YR>
<VL>76</VL>
<NO>3</NO>
<PG>510-6</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:46:59 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Castro-1999" MODIFIED="2009-01-22 15:46:48 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Castro 1999" TYPE="JOURNAL_ARTICLE">
<AU>Castro AA, Clark OA, Atallah AN</AU>
<TI>Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update</TI>
<SO>Sao Paulo Medical Journal</SO>
<YR>1999</YR>
<VL>117</VL>
<NO>3</NO>
<PG>138-9</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:46:48 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Chanock-1996" MODIFIED="2009-01-22 15:46:39 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Chanock 1996" TYPE="JOURNAL_ARTICLE">
<AU>Chanock SJ, Pizzo PA</AU>
<TI>Fever in the neutropenic host</TI>
<SO>Infectious Diseases Clinics of North America</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>4</NO>
<PG>777-96</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:46:39 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Clark-2005" MODIFIED="2009-02-12 16:18:56 +0100" MODIFIED_BY="[Empty name]" NAME="Clark 2005" TYPE="COCHRANE_REVIEW">
<AU>Clark OAC, Lyman G, Castro AA, Clark LGO, Djulbegovic B</AU>
<TI>Colony-stimulating factors for chemotherapy-induced febrile neutropenia</TI>
<SO>The Cochrane Library</SO>
<YR>2005</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2008-10-17 12:24:21 +0200" MODIFIED_BY="Nicole Skoetz" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trial</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2009-02-12 16:19:31 +0100" MODIFIED_BY="[Empty name]" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:45:35 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2009-02-12 16:19:54 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M SG, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-2001" MODIFIED="2009-02-12 16:20:11 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 2001" TYPE="BOOK">
<AU>Egger M SG, Altman D</AU>
<SO>Systematic Reviews in Health Care</SO>
<YR>2001</YR>
<EN>2nd</EN>
<PB>BMJ Books</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elting-2002" MODIFIED="2009-01-22 15:45:17 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Elting 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elting LS, Cantor SB</AU>
<TI>Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>3</NO>
<PG>189-96</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:45:17 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Furman-1991" MODIFIED="2009-02-12 16:20:26 +0100" MODIFIED_BY="[Empty name]" NAME="Furman 1991" TYPE="JOURNAL_ARTICLE">
<AU>Furman WL, Fairclough DL, Huhn RD, Pratt CB, Stute N, Petros WP et al</AU>
<TI>Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1991</YR>
<VL>9</VL>
<NO>6</NO>
<PG>1022-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Carbonero-2001" MODIFIED="2009-02-12 16:20:48 +0100" MODIFIED_BY="[Empty name]" NAME="Garcia-Carbonero 2001" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Carbonero R, Mayordomo JI, Tornamira MV, Lopez-Brea M, Rueda A, Guillem V et al</AU>
<TI>Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2001</YR>
<VL>93</VL>
<PG>31-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gattei-1997" MODIFIED="2009-02-12 16:21:05 +0100" MODIFIED_BY="[Empty name]" NAME="Gattei 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gattei V, Aldinucci D, Attadia V, Degan M, Alosi MS, De Iuliis A et al</AU>
<TI>Human granulocyte-macrophage colony-stimulating factor supports the clonogenic growth of B-lineage acute lymphoblastic leukemias expressing myeloid antigens</TI>
<SO>Cytokines, Cellular &amp; Molecular Therapy</SO>
<YR>1997</YR>
<VL>3</VL>
<NO>3</NO>
<PG>141-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9426972"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gmur-1991" MODIFIED="2009-01-22 15:44:59 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Gmur 1991" TYPE="JOURNAL_ARTICLE">
<AU>Gmur J, Burger J, Schanz U, Fehr J, Schaffner A</AU>
<TI>Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<NO>8777</NO>
<PG>1223-6</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:44:59 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Griffin-2001" MODIFIED="2009-02-12 16:22:10 +0100" MODIFIED_BY="[Empty name]" NAME="Griffin 2001" TYPE="BOOK_SECTION">
<AU>Griffin J</AU>
<TI>Hematopoietic Growth Factors</TI>
<SO>Cancer: Principles and Practice of Oncology</SO>
<YR>2001</YR>
<VL>1</VL>
<PG>2798-809</PG>
<EN>6th</EN>
<ED>DeVitaJr VT HS, Rosenberg SA</ED>
<PB>Lippincott Williams &amp; Wilkins</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hasselblad-1995" MODIFIED="2009-02-12 16:22:23 +0100" MODIFIED_BY="[Empty name]" NAME="Hasselblad 1995" TYPE="JOURNAL_ARTICLE">
<AU>Hasselblad VIC, Mccrory DC</AU>
<TI>Meta-analytic tools for medical decision making: a practical guide</TI>
<SO>Medical Decision Making</SO>
<YR>1995</YR>
<VL>15</VL>
<PG>81-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2008-10-23 15:26:59 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompsom SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2009-02-12 16:22:36 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deekes JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Inukai-1998" MODIFIED="2009-02-12 16:22:47 +0100" MODIFIED_BY="[Empty name]" NAME="Inukai 1998" TYPE="JOURNAL_ARTICLE">
<AU>Inukai T, Sugita K, Iijima K, Goi K, Tezuka T, Kojika S et al</AU>
<TI>Leukemic cells with 11q23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF</TI>
<SO>Leukemia</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>3</NO>
<PG>382-9</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:44:41 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Kaushansky-2000" MODIFIED="2009-01-22 15:44:34 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Kaushansky 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kaushansky, K</AU>
<TI>Use of thrombopoietic growth factors in acute leukemia</TI>
<SO>Leukemia</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>3</NO>
<PG>505-8</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:44:34 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Kritz-1991" MODIFIED="2009-02-12 16:22:59 +0100" MODIFIED_BY="[Empty name]" NAME="Kritz 1991" TYPE="JOURNAL_ARTICLE">
<AU>Kritz A, Sepkowitz K, Weiss M, Telford P, Sogoloff H, Kempin S et al</AU>
<TI>Pneumocystis carinii pneumonia developing within one month of intensive chemotherapy for treatment of acute lymphoblastic leukemia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>325</VL>
<NO>9</NO>
<PG>661-2</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:44:29 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Lechxin-2003" MODIFIED="2009-02-12 16:23:11 +0100" MODIFIED_BY="[Empty name]" NAME="Lechxin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lechxin J, Bero LA, Djulbegovic B, Clark O</AU>
<TI>Pharmaceutical industry sponsorship and research outcome and quality: systematic review</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<PG>1167-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-1998" MODIFIED="2009-02-12 16:23:41 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lee SM, Radford JA, Dobson L, Huq T, Ryder WD, Pettengell R et al</AU>
<TI>Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost</TI>
<SO>British Journal of Cancer</SO>
<YR>1998</YR>
<VL>77</VL>
<NO>8</NO>
<PG>1294-9</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:44:03 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Lifton-1996" MODIFIED="2009-01-22 15:44:09 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Lifton 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lifton R, Bennett JM</AU>
<TI>Clinical use of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in neutropenia associated with malignancy</TI>
<SO>Hematology and Oncology of Clinics of North America</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>4</NO>
<PG>825-39</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:44:09 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Lok-1994" MODIFIED="2009-01-22 15:44:16 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Lok 1994" TYPE="JOURNAL_ARTICLE">
<AU>Lok S, Foster DC</AU>
<TI>The structure, biology and potential therapeutic applications of recombinant thrombopoietin</TI>
<SO>Stem Cell</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>6</NO>
<PG>586-98</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:44:16 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Madero-1995" MODIFIED="2009-02-12 16:23:53 +0100" MODIFIED_BY="[Empty name]" NAME="Madero 1995" TYPE="JOURNAL_ARTICLE">
<AU>Madero L, Muonz A, Diaz de Heredia A, Martinez A, Badell I, Esquembre C et al</AU>
<TI>G-CSF after autologous bone marrow transplantation for malignant diseases in children. Spanish Working Party for Bone Marrow Transplantation in Children</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>3</NO>
<PG>349-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7541268"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Maher-1994" MODIFIED="2009-02-12 16:24:08 +0100" MODIFIED_BY="[Empty name]" NAME="Maher 1994" TYPE="JOURNAL_ARTICLE">
<AU>Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M et al</AU>
<TI>Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1994</YR>
<VL>121</VL>
<PG>492-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mayordomo-1995" MODIFIED="2009-02-12 16:24:18 +0100" MODIFIED_BY="[Empty name]" NAME="Mayordomo 1995" TYPE="JOURNAL_ARTICLE">
<AU>Mayordomo JI, Rivera F, Diaz-Puente MT, Lianes P, Colomer R, Lopez-Brea M et al</AU>
<TI>Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1995</YR>
<VL>11</VL>
<NO>87</NO>
<PG>803-08</PG>
<PB>Oxford University Press</PB>
<IDENTIFIERS MODIFIED="2009-01-22 15:43:46 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-McQuay-1997" MODIFIED="2009-01-22 15:43:41 +0100" MODIFIED_BY="Nicole Skoetz" NAME="McQuay 1997" TYPE="JOURNAL_ARTICLE">
<AU>McQuay HJ MR</AU>
<TI>Using numerical results from systematic reviews in clinical practice</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1997</YR>
<VL>126</VL>
<NO>9</NO>
<PG>712-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montaner-2001" MODIFIED="2008-10-23 20:14:16 +0200" MODIFIED_BY="[Empty name]" NAME="Montaner 2001" TYPE="JOURNAL_ARTICLE">
<AU>Montaner JS, O'Shaughnessy MV, Schechter MT</AU>
<TI>Industry-sponsored clinical research: a double-edged sword</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>358</VL>
<NO>9296</NO>
<PG>1893-5</PG>
<IDENTIFIERS MODIFIED="2008-10-23 20:14:16 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-23 20:14:16 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S0140-6736(01)06891-X"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nemunaitis-1992" MODIFIED="2009-02-09 06:59:05 +0100" MODIFIED_BY="[Empty name]" NAME="Nemunaitis 1992" TYPE="JOURNAL_ARTICLE">
<AU>Nemunaitis JJ</AU>
<TI>RhGM-CSF in bone marrow transplantation: experience in pediatric patients</TI>
<SO>Medical Pediatric Oncology</SO>
<YR>1992</YR>
<VL>Supp 2</VL>
<PG>31-3</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:43:17 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Ohno-1993" MODIFIED="2009-02-12 16:24:31 +0100" MODIFIED_BY="[Empty name]" NAME="Ohno 1993" TYPE="JOURNAL_ARTICLE">
<AU>Ohno R, Tomonaga M, Ohshima T, Masaoka T, Asou N, Oh H et al</AU>
<TI>A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. Japan Adult Leukemia Study Group</TI>
<SO>International Journal of Hematology</SO>
<YR>1993</YR>
<VL>58</VL>
<NO>1-2</NO>
<PG>73-81</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:43:08 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Ozer-2000" MODIFIED="2009-02-12 16:24:42 +0100" MODIFIED_BY="[Empty name]" NAME="Ozer 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA et al</AU>
<TI>2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>20</NO>
<PG>3558-85</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:43:00 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Palmeri-1999" MODIFIED="2009-02-12 16:24:57 +0100" MODIFIED_BY="[Empty name]" NAME="Palmeri 1999" TYPE="JOURNAL_ARTICLE">
<AU>Palmeri S, Leonardi V, Danova M, Porta C, Ferrari S, Fincato G et al</AU>
<TI>Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients</TI>
<SO>Haematologica</SO>
<YR>1999</YR>
<VL>11</VL>
<PG>1016-23</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:42:53 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Parsons-2000" MODIFIED="2009-01-22 15:42:41 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Parsons 2000" TYPE="JOURNAL_ARTICLE">
<AU>Parsons SK</AU>
<TI>Oncology practice patterns in the use of hematopoietic growth factors</TI>
<SO>Current Opinion in Pediatrics</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>1</NO>
<PG>10-7</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:42:38 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Petrilli-1993" MODIFIED="2009-02-12 16:25:12 +0100" MODIFIED_BY="[Empty name]" NAME="Petrilli 1993" TYPE="JOURNAL_ARTICLE">
<AU>Petrilli AS, Bianchi A, Kusano E, Melaragno R, Naspitz C, Mendonca JS et al</AU>
<TI>Fever and granulocytopenia in children with cancer: a study of 299 episodes with two treatment protocols in Brazil</TI>
<SO>Medical Pediatric Oncology</SO>
<YR>1993</YR>
<VL>21</VL>
<NO>5</NO>
<PG>356-61</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:42:29 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Petros-2001" NAME="Petros 2001" TYPE="BOOK_SECTION">
<AU>Petros WP</AU>
<TI>Colony-Stimulating Factors</TI>
<SO>Cancer Chemotherapy and Biotherapy - Principles and Practice</SO>
<YR>2001</YR>
<ED>Longo DL</ED>
<PB>Lippincott Williams &amp; Wilkins Publishers</PB>
<CY>Philadelphia, PA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pierelli-2001" MODIFIED="2009-02-12 16:25:23 +0100" MODIFIED_BY="[Empty name]" NAME="Pierelli 2001" TYPE="JOURNAL_ARTICLE">
<AU>Pierelli L, Perillo A, Ferrandina G, Salerno G, Rutella S, Fattorossi A et al</AU>
<TI>The role of growth factor administration and T-cell recovery after peripheral blood progenitor cell transplantation in the treatment of solid tumors: results from a randomized comparison of G-CSF and GM-CSF</TI>
<SO>Transfusion</SO>
<YR>2001</YR>
<VL>12</VL>
<PG>1577-85</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:42:20 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Pizzo-1982" MODIFIED="2009-01-22 15:42:11 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Pizzo 1982" TYPE="JOURNAL_ARTICLE">
<AU>Pizzo PA, Robichaud KJ, Wesley R, Commers JR</AU>
<TI>Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes</TI>
<SO>Medicine (Baltimore)</SO>
<YR>1982</YR>
<VL>61</VL>
<NO>3</NO>
<PG>153-65</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:42:09 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Pizzo-1991" MODIFIED="2009-01-22 15:41:59 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Pizzo 1991" TYPE="JOURNAL_ARTICLE">
<AU>Pizzo PA, Rubin M, Freifeld A, Walsh TJ</AU>
<TI>The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies</TI>
<SO>Journal of Pediatrics</SO>
<YR>1991</YR>
<VL>119</VL>
<NO>5</NO>
<PG>679-94</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:41:57 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Pizzo-1993" MODIFIED="2009-01-22 15:41:46 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Pizzo 1993" TYPE="JOURNAL_ARTICLE">
<AU>Pizzo PA</AU>
<TI>Management of fever in patients with cancer and treatment-induced neutropenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>328</VL>
<NO>18</NO>
<PG>1323-32</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:41:46 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Pizzo-1999" MODIFIED="2009-01-22 15:41:36 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Pizzo 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pizzo PA</AU>
<TI>Fever in immunocompromised patients</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>12</NO>
<PG>893-900</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:41:36 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Pui-1997" MODIFIED="2009-02-12 16:25:35 +0100" MODIFIED_BY="[Empty name]" NAME="Pui 1997" TYPE="JOURNAL_ARTICLE">
<AU>Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT et al</AU>
<TI>Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>336</VL>
<NO>25</NO>
<PG>1781-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pui-1998" MODIFIED="2009-02-12 16:25:49 +0100" MODIFIED_BY="[Empty name]" NAME="Pui 1998" TYPE="JOURNAL_ARTICLE">
<AU>Pui CH, Evans WE, Gilbert JR</AU>
<TI>Meeting report: International Childhood ALL Workshop: Memphis, TN, 3-4 December 1997</TI>
<SO>Leukemia</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>8</NO>
<PG>1313-8</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:41:19 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Pui-2001" MODIFIED="2009-01-22 15:41:12 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Pui 2001" TYPE="JOURNAL_ARTICLE">
<AU>Pui CH, Campana D, Evans WE</AU>
<TI>Childhood acute lymphoblastic leukaemia--current status and future perspectives</TI>
<SO>Lancet Oncology</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>10</NO>
<PG>567-607</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:41:12 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Riikonen-1994" MODIFIED="2009-02-12 16:26:03 +0100" MODIFIED_BY="[Empty name]" NAME="Riikonen 1994" TYPE="JOURNAL_ARTICLE">
<AU>Riikonen P, Saarinen UM, Makipernaa A, Hovi L, Komulainen A, Pihkala J et al</AU>
<TI>Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children</TI>
<SO>Pediatric Infectious Diseases Journal</SO>
<YR>1994</YR>
<VL>13</VL>
<NO>3</NO>
<PG>197-202</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:41:05 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Riikonen-1995" MODIFIED="2009-01-22 15:40:47 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Riikonen 1995" TYPE="JOURNAL_ARTICLE">
<AU>Riikonen P, Rahiala J, Salonvaara M, Perkkio M</AU>
<TI>Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer</TI>
<SO>Stem Cells</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>3</NO>
<PG>289-94</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:40:47 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Rosenman-2002" MODIFIED="2009-01-22 15:40:39 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Rosenman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rosenman M, Madsen K, Hui S, Breitfeld PP</AU>
<TI>Modeling administrative outcomes in fever and neutropenia: clinical variables significantly influence length of stay and hospital charges</TI>
<SO>Journal of Pediatric Hematology and Oncology</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>4</NO>
<PG>263-8</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:40:37 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Rubino-1998" MODIFIED="2009-01-22 15:40:28 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Rubino 1998" TYPE="JOURNAL_ARTICLE">
<AU>Rubino C, Laplanche A, Patte C, Michon J.</AU>
<TI>Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1998</YR>
<VL>90</VL>
<NO>10</NO>
<PG>750-5</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:40:28 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Saarinen-1992" MODIFIED="2009-02-12 16:26:13 +0100" MODIFIED_BY="[Empty name]" NAME="Saarinen 1992" TYPE="JOURNAL_ARTICLE">
<AU>Saarinen UM, Hovi L, Riikonen P, Pihkala J, Juvonen E</AU>
<TI>Recombinant human granulocyte-macrophage colony-stimulating factor in children with chemotherapy-induced neutropenia</TI>
<SO>Medical Pediatric Oncology</SO>
<YR>1992</YR>
<VL>20</VL>
<NO>6</NO>
<PG>489-96</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:40:05 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Saarinen-1996" MODIFIED="2009-01-22 15:39:54 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Saarinen 1996" TYPE="JOURNAL_ARTICLE">
<AU>Saarinen UM, Hovi L, Juvonen E, Riikonen P, Mottonen M, Makipernaa A</AU>
<TI>Granulocyte-colony-stimulating factor after allogeneic and autologous bone marrow transplantation in children</TI>
<SO>Medical Pediatric Oncology</SO>
<YR>1996</YR>
<VL>26</VL>
<NO>6</NO>
<PG>380-6</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:39:46 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Schaison--1998" MODIFIED="2009-02-12 16:26:22 +0100" MODIFIED_BY="[Empty name]" NAME="Schaison  1998" TYPE="JOURNAL_ARTICLE">
<AU>Schaison G, Eden OB, Henze G, Kamps WA, Locatelli F Ninane J, et al</AU>
<TI>Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>12</NO>
<PG>955-66</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:39:36 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Trus-2003" MODIFIED="2009-02-12 16:26:31 +0100" MODIFIED_BY="[Empty name]" NAME="Trus 2003" TYPE="JOURNAL_ARTICLE">
<AU>Trus MR, Bordeleau L, Pihl C, McGeer A, Prevost J, Minden MD et al</AU>
<TI>Clinical manifestations associated with the aberrant expression of the soluble granulocyte-macrophage colony-stimulating factor receptor in patients presenting with haematological malignancies.</TI>
<SO>British Journal of Haematology</SO>
<YR>2003</YR>
<VL>121</VL>
<NO>1</NO>
<PG>86-93</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:39:23 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Vose-1995" MODIFIED="2009-01-22 15:39:13 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Vose 1995" TYPE="JOURNAL_ARTICLE">
<AU>Vose JM, Armitage JO</AU>
<TI>Clinical applications of hematopoietic growth factors</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>4</NO>
<PG>1023-35</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:39:13 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Weaver-2001" MODIFIED="2009-02-12 16:26:41 +0100" MODIFIED_BY="[Empty name]" NAME="Weaver 2001" TYPE="JOURNAL_ARTICLE">
<AU>Weaver CH, Schulman KA, Buckner CD</AU>
<TI>Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy:a randomized comparison of filgrastim, sargramostim, or sequencial sargramostim and filgrastim</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2001</YR>
<VL>Suppl 2</VL>
<PG>S23-9</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:38:57 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Welte-1997" MODIFIED="2009-01-22 15:38:52 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Welte 1997" TYPE="JOURNAL_ARTICLE">
<AU>Welte K, Boxer LA.</AU>
<TI>Severe chronic neutropenia: pathophysiology and therapy</TI>
<SO>Seminars in Hematology</SO>
<YR>1997</YR>
<VL>34</VL>
<NO>4</NO>
<PG>267-78</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:38:52 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Wexler-1996" MODIFIED="2009-02-12 16:26:53 +0100" MODIFIED_BY="[Empty name]" NAME="Wexler 1996" TYPE="JOURNAL_ARTICLE">
<AU>Wexler LH, Weaver-McClure L, Steinberg SM, Jacobson J, Jarosinski P, Avila N et al.</AU>
<TI>Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>3</NO>
<PG>901-10</PG>
<IDENTIFIERS MODIFIED="2009-01-22 15:38:43 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Yusuf-1985" MODIFIED="2009-02-12 16:27:04 +0100" MODIFIED_BY="[Empty name]" NAME="Yusuf 1985" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S PR, Lewis J, Collins R, Sleight P</AU>
<TI>Beta blockade during and after myocardial infarction: an overview of the randomized trials</TI>
<SO>Programs Cardiovascular Disease</SO>
<YR>1985</YR>
<VL>27</VL>
<NO>5</NO>
<PG>335-71</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-05-13 08:58:47 +0200" MODIFIED_BY="Nicole Skoetz">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-05-13 08:58:47 +0200" MODIFIED_BY="Nicole Skoetz" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Calderwood-1994">
<CHAR_METHODS MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised<BR/>Blind: yes<BR/>Withdrawals: 5 (4 of treatment group and 1 in placebo group)<BR/>Size: not pre-determined; 20 individuals for each arm (N=40)<BR/>ITT: no<BR/>Placebo: yes<BR/>Multicentre: no<BR/>Funding: pharmaceutical</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-09 06:08:02 +0100" MODIFIED_BY="[Empty name]">
<P>Children with ALL; ANC &lt; 0.5 X 10<SUP>9</SUP>/l<BR/>Time period: November 1989 through September 1992</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-17 12:15:31 +0200" MODIFIED_BY="Nicole Skoetz">
<P>GM-CSF (Sandoz) 5.5mcg/kg SC</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>Overall mortality, time of neutropenia, time of hospitalisation, infection episodes, delays of chemotherapy, side effects and rate of remission.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>2 cycles<BR/>CSF co-administered with chemo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-13 08:58:47 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Clarke-1999">
<CHAR_METHODS MODIFIED="2009-02-12 16:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised<BR/>Blind: no<BR/>Withdrawals: 1 patient did not receive G-CSF<BR/>Size: not determined previously. N = 17 (8 randomised to receive G-CSF after first block and 9 following the second block)<BR/>ITT: yes<BR/>Placebo: no<BR/>Multicentre: no<BR/>Funding: pharmaceutical</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-25 14:29:47 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Children with ALL; ANC &lt; 1 X 10<SUP>9</SUP>/l<BR/>Time period: January 1995 through April 1996</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>G-CSF (filgrastim) 5mcg/kg SC</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Delays of chemotherapy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>1 cycle<BR/>Cross-over study: patients received G-CSF starting 4 days following completion of either the first or the second block of intensification therapy<BR/>CSF in interval of chemo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dibenedetto-1995">
<CHAR_METHODS MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised<BR/>Blind: no<BR/>Withdrawals: no<BR/>Size: N = 32 (14 received G-CSF and 18 did not)<BR/>ITT: no<BR/>Placebo: no<BR/>Multicentre: no<BR/>Funding: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-25 14:29:58 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Children with ALL; ANC &lt; 0.5 X 10<SUP>9</SUP>/l<BR/>Time period: March 1991 through November 1993</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>G-CSF 10mcg/kg SC</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Episodes of febrile neutropenia, time of neutropenia, time of hospitalisation, infection episodes, delays of chemotherapy and side effects (bone pain).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>1 cycle<BR/>CSF in interval of chemo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Michel-2000">
<CHAR_METHODS MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised<BR/>Blind: no<BR/>Withdrawals: no<BR/>Size: N = 67 (34 with G-CSF and 33 without)<BR/>ITT: no<BR/>Placebo: no<BR/>Funding: academic</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-25 14:30:09 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Children with ALL; ANC &lt; 0.5 X 10<SUP>9</SUP>/l<BR/>Time period: June 1993 through January 1998</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>G-CSF 5mcg/kg SC</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Length of febrile neutropenia, chemotherapy delays, incidence of infections</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>6 cycles<BR/>CSF in interval of chemo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pui-1997">
<CHAR_METHODS MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised<BR/>Blind: yes<BR/>Withdrawals: 16 because received parenteral antibiotics before G-CSF was scheduled to begin<BR/>Size: N = 164, but only 148 evaluated (73 in G-CSF group and 75 in placebo group)<BR/>ITT: no<BR/>Placebo: yes<BR/>Multicentre: no<BR/>Funding: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-25 14:30:20 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Children with ALL; ANC &lt; 0.5 X 10<SUP>9</SUP>/l<BR/>Time period: December 1991 through August 1994</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>G-CSF 10mcg/kg SC</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Episodes of febrile neutropenia and infection episodes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>1 cycle<BR/>CSF in interval of chemo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Welte-1996">
<CHAR_METHODS MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised<BR/>Blind: no<BR/>Withdrawals: no<BR/>Size: N = 34 (17 to each arm)<BR/>ITT: yes<BR/>Placebo: no<BR/>Multicenter: yes<BR/>Funding: pharmaceutical</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-25 14:30:32 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Children with ALL; ANC &lt; 0.5 X 10<SUP>9</SUP>/l<BR/>Time period: January 1991 through December 1992</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>G-CSF 5mcg/kg SC</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Episodes of febrile neutropenia, infection and delays of chemotherapy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>&gt;9 cycles evaluation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-08-25 14:30:36 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Chen-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-25 14:30:36 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heath-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Including patients older than 18 years of age (up to 21 years)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-24 01:43:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laver-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-24 01:43:48 +0200" MODIFIED_BY="[Empty name]">
<P>Included older patients (22 years) and reported insufficient data to perform meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-22 15:35:58 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Little-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-28 18:09:20 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over study without separate analysis of the period before and after cross-over</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-25 14:30:42 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Ohno-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-25 14:30:42 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Inclusion of adult subjects and data not extractable for children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saarinen_x002d_Pihkala2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomised<BR/>Use GM-CSF after ANC &lt; 0.5 x 10<SUP>9</SUP>/L (treatment of neutropenia)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P>None found</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Calderwood-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Clarke-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dibenedetto-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Michel-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pui-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-28 19:52:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Welte-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Total cycles of chemotherapy for febrile neutropenia, infections and delays</TITLE>
<TABLE COLS="8" ROWS="7">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Group numbers</P>
</TH>
<TH>
<P>Number of courses</P>
</TH>
<TH>
<P>Febrile Neutrop data</P>
</TH>
<TH>
<P>Infection data</P>
</TH>
<TH>
<P>Count of infection</P>
</TH>
<TH>
<P>Chemotherapy delays</P>
</TH>
<TH>
<P>Total cycles</P>
</TH>
</TR>
<TR>
<TD>
<P>Calderwood</P>
</TD>
<TD>
<P>16 CSF vs 19 control</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>none available</P>
</TD>
<TD>
<P>13 CSF vs 15 control</P>
</TD>
<TD>
<P>13 vs 15</P>
</TD>
<TD>
<P>9 in CSF vs 15 in control</P>
</TD>
<TD>
<P>32 in CSF vs 38 in control</P>
</TD>
</TR>
<TR>
<TD>
<P>Clarke</P>
</TD>
<TD>
<P>8 CSF vs 9 control</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>none available</P>
</TD>
<TD>
<P>none available</P>
</TD>
<TD>
<P>none available</P>
</TD>
<TD>
<P>3 CSF vs 6 control</P>
</TD>
<TD>
<P>9 in CSF and 8 in control</P>
</TD>
</TR>
<TR>
<TD>
<P>Dibenedetto</P>
</TD>
<TD>
<P>14 CSF vs 18 control</P>
</TD>
<TD>
<P>1 (4 in total)</P>
</TD>
<TD>
<P>none available</P>
</TD>
<TD>
<P>2 vs 2</P>
</TD>
<TD>
<P>2 vs 2</P>
</TD>
<TD>
<P>13 in CSF vs 16 in control</P>
</TD>
<TD>
<P>56 in CSF vs 72 in control</P>
</TD>
</TR>
<TR>
<TD>
<P>Michel</P>
</TD>
<TD>
<P>34 CSF vs 33 control</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>none available</P>
</TD>
<TD>
<P>septicaemia 4% (CSF) vs 11% (control) per patient per course</P>
</TD>
<TD>
<P>8 vs 22</P>
</TD>
<TD>
<P>5 CSF vs 9 control</P>
</TD>
<TD>
<P>204 in CSF vs 198 in control</P>
</TD>
</TR>
<TR>
<TD>
<P>Pui</P>
</TD>
<TD>
<P>73 CSF vs 75 control</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>42 CSF vs 51 control</P>
</TD>
<TD>
<P>12CSF vs 27 control (documented infections)</P>
</TD>
<TD>
<P>12 vs 27</P>
</TD>
<TD>
<P>not available</P>
</TD>
<TD>
<P>73 in CSF vs 75 in control</P>
</TD>
</TR>
<TR>
<TD>
<P>Welte</P>
</TD>
<TD>
<P>17 vs 17</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>17% (26) vs 40% (61) per cycle</P>
</TD>
<TD>
<P>8% vs 15% cultures confirmed</P>
</TD>
<TD>
<P>12 vs 23</P>
</TD>
<TD>
<P>not available</P>
</TD>
<TD>
<P>153 vs 153</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2009-02-12 16:04:35 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Details of ALL treatment in the included studies</TITLE>
<TABLE COLS="6" ROWS="7">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Cycle CSF given</P>
</TH>
<TH>
<P>Follow up period</P>
</TH>
<TH>
<P>Total cycles</P>
</TH>
<TH>
<P>Chemotherapy used</P>
</TH>
<TH>
<P>Protocol name</P>
</TH>
</TR>
<TR>
<TD>
<P>Calderwood 1994</P>
</TD>
<TD>
<P>GM-CSF D5-11, D19-25; first cycle</P>
</TD>
<TD>
<P>28 days</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>(Intensification) cyclophosphamide 1g/m2 D0 and D13; cytosine arabinoside 75mg/m2 D1-4, 8-11, 15-18 e 22-25; 6-mercaptopurine 60mg/m2 D0-27</P>
</TD>
<TD>
<P>French-American-British L3 protocol</P>
</TD>
</TR>
<TR>
<TD>
<P>Clarke 1999</P>
</TD>
<TD>
<P>G-CSF after first cycle and second cycle if intensification as cross-over basis</P>
</TD>
<TD>
<P>unclear (2 blocks = 60 days?)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>Induction - vincristine, prednisolone ans asparaginase; Intensification - unclear; Maintenance - monthly vincristine and prednisolone, daily mercaptopurine and weekly oral methotrexate</P>
</TD>
<TD>
<P>MRC UKALL XI</P>
</TD>
</TR>
<TR>
<TD>
<P>Dibenedetto 1995</P>
</TD>
<TD>
<P>G-CSF after cytarabine in phase 2</P>
</TD>
<TD>
<P>unclear (3 cycles)</P>
</TD>
<TD>
<P>3?</P>
</TD>
<TD>
<P>Induction- phase 1: prednisone D0-28, vincristine 1,5mg/m2 D7,14,21 and 28; daunorubicin 30mg/m2 D7,14,21, and 28 and L-asparaginase 10000UI/m2 D18,24,27,30,33,36 and 39. Phase 2: cyclophosphamide 1g/m2 D42,70; cytarabine 75mgm2 D44-47,51-54,58-61,65-68; 6-mercaptopurine 60mg/m2 D35-49</P>
</TD>
<TD>
<P>Berlin-Frankfurt-Munster Protocol</P>
</TD>
</TR>
<TR>
<TD>
<P>Michel 2000</P>
</TD>
<TD>
<P>G-CSF during consolidation</P>
</TD>
<TD>
<P>median of 27 months</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>Consolidation (alternate phases until course 6): phase 1 - cytarabine 2g/m2 D1-2; etoposide 150mg/m2 D3-5; Dexamethasone 20mg/m2 D2-5. Phase 2: Vincristine 1.5mg/m2 D1; Methotrexate 8g/m2; Cyclophosphamide 375mg/m2 D2-3; Doxorubicin 60 mg/m2 D2; Prednisone 60mg/m2 D1-5.</P>
</TD>
<TD>
<P>Fralle 93</P>
</TD>
</TR>
<TR>
<TD>
<P>Pui 1997</P>
</TD>
<TD>
<P>G-CSF one day after induction</P>
</TD>
<TD>
<P>unclear (1cycle)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>Induction: prednisone 40mg/m2/day for 4-weeks; vincristine 1.5mg/m2/week for 4 weeks; asparaginase 1.000UI/m2 3times a week for 3 weeks; daunorubicin 25mg/m2 D1, 8; etoposide and cytarabine 300mg/m2 each, D22,25 and 29.</P>
</TD>
<TD>
<P>Total Therapy Study XIIIA</P>
</TD>
</TR>
<TR>
<TD>
<P>Welte 1996</P>
</TD>
<TD>
<P>G-CSF after first cycle, then for 9 cycles</P>
</TD>
<TD>
<P>approx. 30 weeks</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>HR1: Dexamethasone 20mg/m2/d D1-5; 6-mercaptopurine 100mg/m2/d D1-5; vincristine 1.5mg/m2/d D1,6; cytosine-arabinoside 2g/m2x2 D5; methotrexate 5g;m2 D1 (24hs); L-asparaginase 25000UI/m2 D1.HR-2: Dexamethasone 20mg/m2/d D1-5; 6-thioguanine 100mg/m2/d D1-5; vindesine 3mg/m2/d D1; daunorubicin 50mg/m2 D5; methotrexate 5g;m2 D1 (24hs); ifosfamide 400mg/m2/d D1-5; L-asparaginase 25000UI/m2 D1. HR3: Dexamethasone 20mg/m2/d D1-5; cytosine-arabinoside 2g/m2x4 D1-2; etoposide 150mg/m2/d D6; L-asparaginase 25000UI/m2 D6.</P>
</TD>
<TD>
<P>Berlin-Frankgurt-Munster 90 Protocol</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-02-12 16:28:28 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-10-28 17:11:24 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Febrile neutropenia episodes</NAME>
<IV_OUTCOME CHI2="4.801754522549409" CI_END="0.8490848447444357" CI_START="0.4618201762579595" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.6261984610791035" ESTIMABLE="YES" I2="79.1742789993965" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.07104891074159689" LOG_CI_START="-0.33552709730432245" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.20328800402295966" MODIFIED="2008-10-28 17:11:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.028430874118063776" P_Q="1.0" P_Z="0.0025867390072176386" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="3.0130058856822846">
<NAME>Febrile neutropenia episodes</NAME>
<GROUP_LABEL_1>Favours CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Rate Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.2706092761041918" CI_START="0.56355151476833" EFFECT_SIZE="0.8461996113371882" ESTIMABLE="YES" ESTIMATE="-0.167" LOG_CI_END="0.1040120215849181" LOG_CI_START="-0.24906637854060418" LOG_EFFECT_SIZE="-0.07252717847784307" MODIFIED="2008-10-28 17:10:42 +0100" MODIFIED_BY="[Empty name]" ORDER="20099" SE="0.2074" STUDY_ID="STD-Pui-1997" TOTAL_1="1" TOTAL_2="1" WEIGHT="56.10963153822442"/>
<IV_DATA CI_END="0.6747665865430945" CI_START="0.2691163259511813" EFFECT_SIZE="0.4261346085981487" ESTIMABLE="YES" ESTIMATE="-0.853" LOG_CI_END="-0.17084643117959014" LOG_CI_START="-0.5700599549473575" LOG_EFFECT_SIZE="-0.3704531930634738" MODIFIED="2008-10-28 17:10:42 +0100" MODIFIED_BY="[Empty name]" ORDER="20100" SE="0.2345" STUDY_ID="STD-Welte-1996" TOTAL_1="1" TOTAL_2="1" WEIGHT="43.89036846177559"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Length of neutropenia</NAME>
<CONT_OUTCOME CHI2="5.221815963394083" CI_END="-2.122173777521611" CI_START="-4.756991456975513" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.439582617248562" ESTIMABLE="YES" I2="61.69914807376633" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.0734679256959695" P_Q="1.0" P_Z="3.10087858030843E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="70" UNITS="" WEIGHT="100.0" Z="5.117210275478681">
<NAME>Length of neutropenia</NAME>
<GROUP_LABEL_1>Favours CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3276612225396862" CI_START="-4.327661222539686" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="7.5" ORDER="20101" SD_1="3.5" SD_2="5.0" SE="1.4427108073637664" STUDY_ID="STD-Calderwood-1994" TOTAL_1="16" TOTAL_2="19" WEIGHT="21.7063296434985"/>
<CONT_DATA CI_END="4.803705045105578" CI_START="-4.803705045105578" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="5.0" ORDER="20102" SD_1="6.7" SD_2="7.1" SE="2.4509149571097173" STUDY_ID="STD-Dibenedetto-1995" TOTAL_1="14" TOTAL_2="18" WEIGHT="7.521223252045026"/>
<CONT_DATA CI_END="-2.8340118659679012" CI_START="-5.9659881340320995" EFFECT_SIZE="-4.4" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="8.8" ORDER="20103" SD_1="3.32" SD_2="3.22" SE="0.7989882193675054" STUDY_ID="STD-Michel-2000" TOTAL_1="34" TOTAL_2="33" WEIGHT="70.77244710445648"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.2781762016295889" CI_END="1.3228250043725343" CI_START="-3.5508250412974363" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.114000018462451" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="0.5978991578069747" P_Q="1.0" P_Z="0.3702517442326798" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="0.8960019264835056">
<NAME>Length of neutropenia excluding Michel 2000</NAME>
<GROUP_LABEL_1>Favours CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3276612225396862" CI_START="-4.327661222539686" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="7.5" ORDER="20104" SD_1="3.5" SD_2="5.0" SE="1.4427108073637664" STUDY_ID="STD-Calderwood-1994" TOTAL_1="16" TOTAL_2="19" WEIGHT="74.26666789749673"/>
<CONT_DATA CI_END="4.803705045105578" CI_START="-4.803705045105578" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="5.0" ORDER="20105" SD_1="6.7" SD_2="7.1" SE="2.4509149571097173" STUDY_ID="STD-Dibenedetto-1995" TOTAL_1="14" TOTAL_2="18" WEIGHT="25.733332102503272"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Length of hospitalisation</NAME>
<CONT_OUTCOME CHI2="0.7082554004662037" CI_END="-0.1535877669635659" CI_START="-3.001612102321956" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.577599934642761" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.701785445212325" P_Q="1.0" P_Z="0.02990418259469666" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="70" UNITS="" WEIGHT="100.0" Z="2.1713571864711323">
<NAME>Length of hospitalisation</NAME>
<GROUP_LABEL_1>Favours CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="12.754702720131238" CI_START="-14.754702720131238" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="6.0" ORDER="20106" SD_1="22.0" SD_2="19.0" SE="7.0178344238090995" STUDY_ID="STD-Calderwood-1994" TOTAL_1="16" TOTAL_2="19" WEIGHT="1.0718277170604449"/>
<CONT_DATA CI_END="2.718589124172683" CI_START="-3.5185891241726837" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="6.2" ORDER="20107" SD_1="4.0" SD_2="5.0" SE="1.5911461377717735" STUDY_ID="STD-Dibenedetto-1995" TOTAL_1="14" TOTAL_2="18" WEIGHT="20.85024106024637"/>
<CONT_DATA CI_END="-0.2884286003933798" CI_START="-3.5115713996066207" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="7.7" ORDER="20108" SD_1="3.38" SD_2="3.35" SE="0.8222454148741967" STUDY_ID="STD-Michel-2000" TOTAL_1="34" TOTAL_2="33" WEIGHT="78.07793122269318"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Delays in chemotherapy courses</NAME>
<IV_OUTCOME CHI2="1.6372126476385962" CI_END="1.195606727295673" CI_START="0.4747771320901087" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.753423342545929" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.07758835000990731" LOG_CI_START="-0.3235102072537786" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.12296092862193565" NO="1" P_CHI2="0.6509819062370867" P_Q="1.0" P_Z="0.2294818835551643" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="4" TOTAL_2="4" WEIGHT="100.0" Z="1.20169463210589">
<NAME>Number of delays in chemotherapy</NAME>
<GROUP_LABEL_1>Favours CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Rate Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.6287564544617652" CI_START="0.3118550406997716" EFFECT_SIZE="0.7126962258888352" ESTIMABLE="YES" ESTIMATE="-0.3387" LOG_CI_END="0.2118561497530734" LOG_CI_START="-0.5060472317943362" LOG_EFFECT_SIZE="-0.14709554102063135" ORDER="20109" SE="0.4217" STUDY_ID="STD-Calderwood-1994" TOTAL_1="1" TOTAL_2="1" WEIGHT="31.21549324173354"/>
<IV_DATA CI_END="1.776936001246049" CI_START="0.11114823329631252" EFFECT_SIZE="0.4444134305116268" ESTIMABLE="YES" ESTIMATE="-0.811" LOG_CI_END="0.24967178638368734" LOG_CI_START="-0.9540974360307619" LOG_EFFECT_SIZE="-0.3522128248235373" ORDER="20112" SE="0.7071" STUDY_ID="STD-Clarke-1999" TOTAL_1="1" TOTAL_2="1" WEIGHT="11.102370833405507"/>
<IV_DATA CI_END="2.1711447335246206" CI_START="0.5025528072936444" EFFECT_SIZE="1.0445644455339314" ESTIMABLE="YES" ESTIMATE="0.0436" LOG_CI_END="0.3366887754930875" LOG_CI_START="-0.29881829667112403" LOG_EFFECT_SIZE="0.018935239410981748" ORDER="20110" SE="0.3733" STUDY_ID="STD-Dibenedetto-1995" TOTAL_1="1" TOTAL_2="1" WEIGHT="39.83468835821389"/>
<IV_DATA CI_END="1.6590944047126293" CI_START="0.18639784943222149" EFFECT_SIZE="0.5561039732311448" ESTIMABLE="YES" ESTIMATE="-0.5868" LOG_CI_END="0.219871098670097" LOG_CI_START="-0.7295591026317534" LOG_EFFECT_SIZE="-0.2548440019808282" ORDER="20111" SE="0.5577" STUDY_ID="STD-Welte-1996" TOTAL_1="1" TOTAL_2="1" WEIGHT="17.84744756664706"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2009-02-12 16:28:28 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Number of infectious disease episodes</NAME>
<IV_OUTCOME CHI2="4.906753096394446" CI_END="0.803530386269814" CI_START="0.39294540942941236" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="0.5619106482544765" ESTIMABLE="YES" I2="18.479696829676264" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.09499769532903507" LOG_CI_START="-0.40566778049062036" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.2503327379098277" MODIFIED="2009-02-12 16:28:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2969997734906793" P_Q="1.0" P_Z="0.0015852231128505637" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.00000000000001" Z="3.158612134794854">
<NAME>Number of infectious disease episodes</NAME>
<GROUP_LABEL_1>Favours treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Rate Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.163714347389584" CI_START="0.4897665891011825" EFFECT_SIZE="1.0294245944751308" ESTIMABLE="YES" ESTIMATE="0.029" LOG_CI_END="0.3351999248536247" LOG_CI_START="-0.3100108449032361" LOG_EFFECT_SIZE="0.012594539975194292" MODIFIED="2008-10-28 17:18:21 +0100" MODIFIED_BY="[Empty name]" ORDER="20113" SE="0.379" STUDY_ID="STD-Calderwood-1994" TOTAL_1="1" TOTAL_2="1" WEIGHT="23.1843891081031"/>
<IV_DATA CI_END="9.116299676621347" CI_START="0.18089039483419636" EFFECT_SIZE="1.2841538256497513" ESTIMABLE="YES" ESTIMATE="0.2501" LOG_CI_END="0.9598185931388592" LOG_CI_START="-0.7425844932908526" LOG_EFFECT_SIZE="0.10861704992400327" MODIFIED="2008-10-28 17:18:21 +0100" MODIFIED_BY="[Empty name]" ORDER="20114" SE="1.0" STUDY_ID="STD-Dibenedetto-1995" TOTAL_1="1" TOTAL_2="1" WEIGHT="3.3302288358770373"/>
<IV_DATA CI_END="0.7924460345269562" CI_START="0.15705344316753275" EFFECT_SIZE="0.3527837556448936" ESTIMABLE="YES" ESTIMATE="-1.0419" LOG_CI_END="-0.10103030350158415" LOG_CI_START="-0.803952537888412" LOG_EFFECT_SIZE="-0.4524914206949981" MODIFIED="2008-10-28 17:18:21 +0100" MODIFIED_BY="[Empty name]" ORDER="20115" SE="0.4129" STUDY_ID="STD-Michel-2000" TOTAL_1="1" TOTAL_2="1" WEIGHT="19.533690901679716"/>
<IV_DATA CI_END="0.9012392753884094" CI_START="0.23144442250788497" EFFECT_SIZE="0.4567130429861787" ESTIMABLE="YES" ESTIMATE="-0.7837" LOG_CI_END="-0.04515989028066638" LOG_CI_START="-0.6355532806544905" LOG_EFFECT_SIZE="-0.34035658546757847" MODIFIED="2008-10-28 17:18:21 +0100" MODIFIED_BY="[Empty name]" ORDER="20116" SE="0.3468" STUDY_ID="STD-Pui-1997" TOTAL_1="1" TOTAL_2="1" WEIGHT="27.68955009881944"/>
<IV_DATA CI_END="1.0481672626139455" CI_START="0.2595403298180197" EFFECT_SIZE="0.5215761469270564" ESTIMABLE="YES" ESTIMATE="-0.6509" LOG_CI_END="0.020430591267983553" LOG_CI_START="-0.5857951478096368" LOG_EFFECT_SIZE="-0.2826822782708266" MODIFIED="2008-10-28 17:18:21 +0100" MODIFIED_BY="[Empty name]" ORDER="20117" SE="0.3561" STUDY_ID="STD-Welte-1996" TOTAL_1="1" TOTAL_2="1" WEIGHT="26.26214105552071"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-02-12 16:28:29 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-10-28 17:11:25 +0100" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Febrile neutropenia episodes, outcome: 1.1 Febrile neutropenia episodes.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-08-25 14:09:54 +0200" MODIFIED_BY="Nicole Skoetz" NO="2" REF_ID="CMP-002.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Length of neutropenia, outcome: 2.1 Length of neutropenia.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuUAAACgCAMAAACc7uI6AAADAFBMVEUAAADAAAAAwAAAAMDg4ADAAMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdCQkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYAAJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkAmcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwzAP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8zzAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBmMzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNmzGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZM5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZzMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zMM//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP//2b//5n//8z///9BjlLGAAAgi0lEQVR42u1dfXAcxZV/+piZnV1pV72WggzGWLYOrgghwZZtfZmEtQMhJHFdArmqpCAkf1yoC4dzVb5cLh8VktSFwF3qLlWQVJKqA44iFwg4hITveC9GWtneGDlF3XEXTvIaG1tgyTOSrdVqd/Vx3T0zO9+7s9rRei31D+T56Df9Xr9+/fpN75uZOgQMDCsc9UwFDMzKGRiYlTMw1DwaxJoTKdaBkSrjgoF3TnxofPBn0kN1DR86k/hZGdeXzcoJrYtzlkpT/mrjzYaBt4qIiSlOcc2zhC+C+kAT1In5C9Fpbza0dhcX8zQXzhAxo4v1fBj/za1qXx6Px8ugHts18M7RbR+Cx7Y15367/fryri+PlSOu7VlmdVwCnyjRiHfqr8vgpkC6952T6d53T16QXjsAJaw2PtbwgQEi5nTvO6eme9OnWMSSFwVeDMdCeDcUy+wVhDB2BzH6F4sFg9CGy0NthLK9T4xK8Rn4CtayGJ9dAqsQL4gtsSa82xRrXRR4I6tQAFqDnBCk7lHai4VKAmg0KCRkOLyj0EGYJ1L6DSEHOYEwDwv8XgnaQjwfaMUcHxYD2gJZNATkDN8Pt7bjv6i0lxcWJXymSYTCPqWXsIy4LWpdfmLokzA3RHVE+dH+i6o60sR8ET6ii3lTVCJ6lJT+LOxTeiwfF8prda1cKw9L2XRP7uD2Mchvv7p9OPhcV0QvPDsFf9EzHdk+TQ4C8Ce1KZvFgaWwiryQm+759MFtechvO5jb+VzIyOqF0zDd/W64u5kcdAyH3ur5IEQ0moVg3x5s/nGFrqUrJHb5b+YDczBP2tXR9UrTcAdMC7m3es/j4y839WrmgzXwWfxvDotC/rCcTa/s3IDPjJ8i+0G6T+k7ukLh7jBs6HqO1OUnGu+AzzRSHVF+tP9miI7Evj0azXupuy+IuWFncKqrQ+nPwj6lx/K1bI/o7ViJVh7DXjRzebgZFgLwA1gDj8/CaBiyOgF2oKMQzn+f9nIfROnJc0PQ861QUr2+DFYznwqH4dEAZrQGhK2weRQME8I1UViAy+aeoqdmYWRtPANdGk1qHB7V6TIwegy2+q4NrjffiycM3P7ACOaaqQ9/ARYV5gsaTbQgB6hyXkOMCTJRsj9K9yk91uQ4bkEOwiMw66+Yb7SOcApvwk/pP8J2QpctSgUvYCuMZmi34v4s7FP6HGwex9NzoR0r7+6zA+KpFLR84GTTJesTXz588KcnT/zz+rt+1nF8oQNSuDTVAXcBTKZ61357mqj11PrX7qdNOfPV1OXrvjunXF8GK/T+t0f3rU8MvzbbEPvNPevvur/jxLyRVWS0d+2eMLGJD5JDwhHTnJwnhR3rUwopLmgkpwfppb5qY9/ZdfF9kKq74ndPwol59IG3z1yyPqUypxQpkJ4k4qiipKBh/ZNPAtEXlsqwj+nVFtC6Ts77Keajv3vrstc7IaXyU/qvuJinCOlbVI/GfUx/vSKmWtfKjVhm4CQORKJC3wf7A9E7QZJgFwziqE8rl0/fnuyjkQUPV6meYvL0UVhCz6XhBI57o0/2tfQ9Ea0nrOoIq6RWLo0d3d9HJl/oVPhTGifg0/4rdG0in1hLuhyeiuOZHkv7po2mGRqNh3WENG/fB0goLaB1ZX0Vc9tQLsHp/JT+s+BKs5j1Sots+zjIV8Q0y74CrfxOuGoTmb86ewZT8ARsGsYtvxNaC0GaeOvfncCdRfb4b0jRWBACsWj0WbMavergqmESw/LbB4/hMTO8CYf69dC2SysP3togwefI3hPQORYTNRoVndrQC8CmjSD4rwqun1NG83Abvhuvh+Zh2+hCMGE8xpKMYY3Y9vGtLDkKaHX5ivv7HzDwU/vPLOYsmEIHHjbmNdGM+2pbgxbZV6CV9ySuJcYTDQMfhdSR9C1HpvC5ab6wbnX43CWHybIIjP/qxfZ08vdw/nCavxdvy4Y4NPVJYkyDwK+B40fuS782BcG68wV7nUqeW3vwIbKXOjK94fA5jUbFU4OXKzupzektR6b8V0WDMnSP779l6vAkBBOhF603F+07jprMB+trw+Epw35BK8c3p6849KpWl6/4Ftxr4Kf2n0nMtXN/NA3G40e2hJJT9n21rVOmdlSCOpatxbDiwX7hZ2BWzsDArJyBgVk5AwOzcgYGZuUMDL5audQk8DtDSWg1/+hfJCckubiTF0J5D5QlEYvF8tBaRgIK5s0R3vgS7mZkqcpQT2vQuSWU4UCsTJk1HeHr+AACd7YDIRe2SZD4GC9BMhawlat7AyFXJYkxou18TDTwdNZ74WS+iRfChB+ljQgtAHvVLK9Wkef35ivqN5tsg+XKtmiWbXEZZDPmsVw6PXn+jRu+M9d9uSkPo0haxs93PP7A9A0fea00ZUl0APzbv/NrwXMVCu8zJGtl4stdb3B6SSpF0lO0o+51KceWYIbTmWfKYEjx4HZFR5jD+L9sNXK1sH3Lje0/zd67C9Z/jntq7d0vahdaKA3XWpV05tLJLAC69ExWPUHycByzdgpc0daHn9ryxbqn23f/GBPWhWfm8q8rJW3nuFPfbD6b9yXxhsg2haV6qlzZes2yher8l83oy9X8bDVfmo64fIg4LDHWht0HdT1anncTHRx5uBpf8VONGiBys5iHZDDQomWBQ1jgI4Zs7YfVRG0HeMhPNkLhTdPqokFoc6CgsvKkNWpdFnjI27ZhTs9hpzndDqC55wJlS/LWrbnAEqyFQfwnwbdJrjdNqcaUQgtVYKsYiNJrXfAKzdDL4a3JNbYKIkhBPq/qThINs1sGdozCR2Fe+WVyYXwe1qi/6mb6A1ExnvYrLHiFphSWJdusXbbAcshWb9yl+dlqvjRF4/agRJIK8vAYTdCIaHne4/Q5jwa4ztyLi4d6fgRbu3+rPDRy9iREup4LbWnRCfaEut0STbzkJxsnIQPvP8Fn7ASKrDSPuVCXCV7ytu3q2mzg6jRgwzT3PEvY0rz1xyzlIraDf8J/fwMNHV2hUNcGRc+hb9PS8XO9mayhA6zYdrh3AFp7D20zn54Qen63sVvk1Hzsx3oOLRhExl24H74Dtwm4M+vH6qXcMc1RvOln8OsmW6AgW1CRTU+oq6uSbAYr1/OzdXcHI38AeAd3yt3EK0IhzztDPeMB6xXHR+FZCEBYVsbjGkwbHgWDzRwfcU1n8pKfbICRdxQesRNk9Zx0XNfdYMvf9JK3bcU5E9c6BwpDfrqSt24uTvTm5wZ7BufybwyOY22OQB85G4AR5bE6mSuRVMlBP66dN94NUL0O3TcjpLR87K/AaMpwReev8ebriYeC3ZdDYIO4kd/EU8ejJeb7BRfZUkMfmxlKaf36LIweLybbL5dDNoOVc6eHh2D7B42l/RDFI1NMzI3NDY0TX02O52kP09F7+jXzFdEoDGAT2capZoBpt5mkjTqbBsFLWA9nKI9bb8XXtVw734z501r6nDyHgbdjGmxBVsB1fXcfrcuEN6AF/xEZv3orpkbXLvxBY9jv2pEGHTkn3w6QNirPCqD3LRyzys5BYz+/jetvpNaAW7q/ICuU4E1xbFCU8oPHCsfqc6vRwGJ/Iqrpro/IoOHE4fSXEvgmJMuN4nBrMnssc3wm/Wk64sDfZ+JcZevt5wuyLZpk222T7Z7lkM24kmjIz07QyAUHkDSRmuv/s346RNU8b/2KqdPD2KoLed80NbsBpLweV9BTAxpB0l12L/nJpgGj8Ca4yuBAjCGwJusM3O5Ql5e8bTtXXUfNjlm+an46gZK3bonL8FzWiP8L0KxhLaW6zi1h3c6f7/1eH2fzc8nMUCKb13SXMFYXTWdnFnht5ANsFKJ93KPKiLvSVyvHsm1wlm3QTbY92ZlFTpdteJlkM1i5lp9N8qXrYKyVTuadJG58HrYpz1aqed76FZnob/AVhbzvjk1YvAwMF7pfzcRugDaFYFenewJ26fxkI+5WeRNr/ga8YCcIKLLigYrrutKprtJ52/ZK9Rx2a063ucXEF6l567ZZfRxf2If3aEtF5S6s8wlDVFPMjz0Pw6S1lhW2rX0vB/saNd1xsGlDYcEO3/i9uoMHUWgVaXZ3VoBOxQvJA7NSxs8scw666O2+WbZdfS+HTLJ1mGTrF3TZPl6QTez0UzaDlWv52SRfWk58gVjA3KHpH5K+HYShtTTEUvK8Nbya/Bi3Kzmp5303zAzFQT74A0TcO40Xj9ySPjIJ8tD55xV204fPuolSMj/ZhDso7/8kCrvkxaM77ASqrD8ZXIfrer/keANbIm/bDj2H3ZbTrd15qPnpiXVa3roJ4wkQOOCGIPEmyUe/4tABunRzKF2vqQzota64ZhAGr1FmWx1tO4eulw/uHFTzseMHZ+pBo3mpIXjfUQkONJyLbMbRemv9OGwJUcm5yHx75IiPWeajWLZRm2xdBtl+T2Sr8yDb+D4/ZfOSXy7Bpb2vT3iukg8eG/nqYadFoBjEgcEBQiDVfNPBTBlXtJ2f9YVmOVB7snmxcmGxPljGvcDAjfPABccdZ/Mcs2jHiHZ2DhoObCvjipA44QvNcqD2ZGPPCjEwMDD4j09VmV8j8+UM1UeVrY5l3jKsfDArZ2BWzsDArJyBofZhTsWQTfcFMjJuSkMjVLZqXYUq5SXeccgu9yr6ebnE7YxJHncuBUG93R2VJCvGVjsrIzN7mf6DSqpY465rt8DFUCVy61JzqbzMN4P0x/JIzVi5jJZujBaD0eoqVCkvtTYXmYznkXd5it30y+UtACBYMlvtrGxhTxVWzMgt3A21IwuJVf/m602lSIYVjkaro0AyMvtJg0fCPaD5GqIik7MoOATZf6WhoudKjEuDPKjkePI+55QiK6oGJ1V54KvTlyZ2cgD69ais8ewJ7g9o/spebDqKV9XKCy3XHYBizLrvMXSL2VmohK6aq8D2ZQ9eE3kYIrKXAKNkdR65eqoCObJHXuhd4zgPg2t5EC+jOFblfKbGktpApmkSyep/DlfJzvNrha5dHUlFrB95dIQe3bTHsM1zdCd7nwvIXCl7ipM9cC9Mw6j80hV99+naMeVbqtJh2qaCaB+5Fyi1+hNGl0uHylJDOY11HI4W3+12Q2u8UD1yGdzFS31FpAatXItCKp3rzKGfDFVQZ4VTxrIAeWNnCFjkpQ0qdHHo+YKg3hpyyMjivGXzlgQrzssAcpFwBSHk89QoVzDPLCHA8JmsUkt0467ruXi4KC+L6i6OiAWp86I+zepxh81I1XP6xuyEzMUV+EKXCpC27OORhTcqz9VVRiabIhAZWQVAHoV0E8JGIaOyrl9pYPnlKwMyqqC46jFOtddY2C/8K8XML8ilF/UaC8PFBlRB8cqfzpkvZwBm5QwMzMoZGJiVMzDU1N1nIcfaQ8qHbFzttRA75Zd7TNp2WQFw+REKmcUuJavXbMMi1Rl5eVNRsRVpe1J7ifxyU069OXvfW365Y+nKz2VptN5sEzVU1mjn/HK/E1n0vMlS2euWH28rWq8w8JLLUUPJ2gr54sXyy025opbscU/55c6l1c4vn4JfRS6glVNtab5ZNrgCNbHckkuuOgLZmG3ukoix9N8dZE9JtcWeAiqzEz3OYqWq9chWRhXqpxZQ5iipL3+JHvls5eZAREbGcW/OJdccATL7DFRirl2CCt2qRF4ME5Vr7SUenfP4AEKZz2LIngMhqGBwycvjtsuUeKrqS/SN3iR3SmLxOsQLzzSipapQRq7DcHn6zL+KvWaKFFJyPOaXV8j4giawRGrjKQrXyUj2PlGZ88uXJb3c10DEr8nRNZT2xBQtffha8sudGBcvXS13n2W6dOTlyiqo0vMjOz70q7+m4VDbkoMKL/nlqzX7vN5N8XJRB1563UJ22iz/nY27EXjNcL8guUvVaaX/Wf4Xoy83rhQrqyrmaMOcS66V0RnWFpbY0s+XqN/S+eV+h+UeRPXO1WNtyPCCFvf8cltOPcsv9waWX74ywPLLy4pYGC5SM7/w4dLFe/fJcHGA5ZczK2dYRkwZDyI1KSKLWBhWPpiVMzArZ2BYWXG5/gJQ5zQo/YVEyG3j56KBW8ahe5K16xKCh8Q/W62lyku1uBiZ/rpyW6VFfgOwaMSWW67/3CFrtVtfeuvYiFWWX669Oa7k4qopP9EhjdkPI3fYM/IH8Mjb2xvUbbVCZVyLk+mvK7dV6p5fbtGIQ245MvO2NdqlEavr/eUWaze8E9XokC70uEfWvUoW0ZaNa0ky/3+JcfuWQRFVID+8UL3zaVSrVq68tBkMcYs1ebxqML6QXva5xlqAXLb5l9aIPThaxk7Ta57y36dUxZfrAqMq+aEy3Qiy7JX4Abus1yi65obYHk0q9at6GW8IN2UILTVORpbvDhXpOj1vZhW/v9x9eqq6q3MwJWR4YMfb+/RLp2yXisuX8Kbvct4QrjF1zC93yBx38uKmrDqru3d4yLlq7y+/WKwcVd2Vy8YlHe8vFPBUo09DsJLaigUssrP2i2kEOfeXjIqcWU2ot0ycyM2By1U1cj0T2pYT7fBm9VIreo71LPVmy3O84u8sWEQjpVal3AfXqnx/uTlQRA5BKxTeve1X/njZLs+WZC2DD484lnodul4uG95dgLxE2kUe6rMzLfX+cl0jbhn9tibI1q5j+eUMFx8qyi2/IHEMyy9nqCScugCXr5i7T4ZaRqU/i7H3lzMwMCtnYGBWzsDArJyBgVk5AwOzcgYGZuUMDMzKGZiVMzAwK2dgYFbOwMCsnIGBWTkDA7NyBgZm5QwMzMoZfEcmIAwwK2dYyRgIzI7lrxFbmZUzrFg/Ll4zBnAWTv9fSKpVK49RaEetQUMB3UQDkG/ihUUJkgplRGgBWMyo9CLP780T2kBtPWGFAvzNZA7NC7EqclWVKTUJ/GLeXBTCcqjn84u80EQNIr+X55uS0ML/BOCHtim/LcQLwTZlX21HUm2O3mUSHzP1IxIEk1NtDQr8PZosQUwwEOL5UNJQQ4U2LoROa/tv1+2tJTtvEAu7qVQHxFPaUfe6wm4HkF3p9P9m0daHn+r9Yt3T7bt/nEpBXXhmLh+qU/rhHHfqm81n85g2mD1zf+00MHrdxOTb/4E7N7odUtVjm0qlptoP57+/Y0LoncwaDbaOyKGe/3vxLNe1N0fGYp30zLF/qLsjsX9+7OM/tfmifETY0vea0iClHU90K83BfaYS/Vg9g1mfvySZy1wvibNzc3olCwthKSzl6EhpJrS/mEuPHf7HfKrDD8VkmienM2tUl4e38Yeax1zNoCNVXSNwiFj2CkIYeOwTIC8KvBhVT28caYBZ2DEKH4V5uJeqbXwe1gTURvYHomI8TXaf691UQ8M4OyBzOSxXPltlxtL2wUmsq2MjkDOeft88+Vc9/yCMjsIOciIHI5tBhEe5RfhzwVbXdG78BDyuuHKlHfmclWasT2d9PiHCmoQ0ns0YCGaz4+dVWW5S+izHCZD3pbFtOB5fg4OVNcTEle3E9HtaasWf2608Mhx8riuCtRGHsJRN98yo5/MwAnWA5d4P34HbhKAE9WP1Uu6YVvqmVsHVkK0hK/9sfZDICj8KVpnxxqzIYV1Fo7BoPL2bzurq+UWyuZycoHt3YD3eKWWPOdR28y0HT9AdtR2NL1sp2g/prrIvMA7znwv9Vchiw5tgJ90m39aEhDt9WVd5k8bjlr/xVHu0Vq08C6Nh1U4zl4fvhoWClUeBg85f492vJx4Kdl8OgQ3iRv6XfAsp7YNCg+pgvoasfKTvbKh7PbS+WGW/Is0m8LTcr1iwAXuontTz1P0+ougP41EQQ1s2Ch1Ci626x2/vuYIG10o72u663kKQDBZeqyJ1EdZ9I0LPdnNFrWlQhsK02lkDM9DjQ1t/seBSsLBQq1aOvco21U5brv3uPqVDqPECnNid/lICKynLjcIcTGaPZY7fk/40KU1AwYoszuvC3/mP4BE6+7Uqc+3sncWmNKhpzgL1fKJwIqGofjJ32+xENjxrv73YrQQbajvST1sJbggVdsVFgVrxyG5zsNR6vv9rpjcMDezqP/p5H9r6+dxr7aAGK4a/tivOTNbuSqIkwS66MwO3/8lg/RJE92RnFjntGGBYiPZxj5IjDq4sXO7UrRcMqvls+1aM3GlUD2epj95JlOmgDvV8HdnsVPpBStLO6Gzkesfnzas1hq5S29F9rbE5hGS7fqYNGrSBVG+gSJ6HP+4yCpH/8OLrPr1Xa1d2Y+MaNVDRtldkztVIwOJg5QHYNAxDWEkSjtmu1G8kebL+xOdf7RdAFFpFIIszHxegUwn9xM5ZKROj/qS5pl7YJcDG/8YBWDweB6jm2/lE+AQdY8ObqOZsY4+ex+obhufJ8isHm24CsiaRkWFozNgrRHKRb/svTIzp1HaYm0OO1DNkSMzDKBVgUyfMqsvApHRX3XEJCuvCxNveEZnwrb1yLtKujW9S97qmc1zNGIHdylNH0rccmYKfDK6DnsT79WgWx+TwUkPwvqMSHGg4F9mMQ7/W+nHYEqJrkeP75tsjR+gENQcP1pCVnzuyZefmuerzXaTT9vHkLen9Z+2l6vmJ/dO3JKk7Pbs5nU7iGHmggQNhg2ghb+KmPnxkyivrOXqPNHUE1yirPp3ecPV+1rw0nh15n19r5dTOs89cou1fGk1zNWQE3t95K60NeNNzOHc6CgxVQqzEDNWazlRaRRlA6XfJck94vATHeK1aOQzcmPFEFwxIzPiqBn6xvujCbWhCLBXTLULOP3mi5+tL/7xfw1bOwODXBMTeX87AwKycgYFZOQMDs3IGZuUMqxtyFa6Ap6vBRGZWzrCaYPwxXv9Ct/G4nNGDnL6bisDwJVgywBw+rYpMxBYS+jlt6/ejdRr1a8fIYSwj455CJRs/hOksDTJu0Kr94PEKtfKKgZzs3vydbOQw+SAzsexgWE7Hhm8oo6Ik6p5qtUY6uzRmGej/zMhXqJVrXydGmhtEhV3NUAoFBtdHjuQCvWZ5yr5c+PSxqwEjp7Eiq59nRiXGk9fJxszT8TPJaHV80PhCBuZVYVLCyhVPhgx+1ezeDJ5Sc3i6Rcs2M0SGYEbWAhCwxinuQZA+UBwM3Gz+ctExUBh0upHbpLHHRqvM4tFSXceyXrIUJi5WLntrOpKL6QQ5zvHI3V8bAxRDFGJn5259hfgaLalHkdO9hax8p16bnhhWSsSCNIuRSxu+7Nd8gi6E//FaFXK+p2ZYCXE5Km0/ZcTJDjbiElk4uXKXi5xpikYsrrYqF5kqZCQzK1mxayxFFhRl55AY6SELGHdlVHSMmJb2nBjKTkPJxWKX5nORL3HgKg3Ll6LzajNxtHJUWOVG+q2huquEqoBM94yGI7OlIrmkgEhbnyErKeraDt0gtdTJmcqFe1bXhT69XrMQctEVcO0qw0I/Wo1xuYxKLgzY74rKuC8sU6OeWTjLvaT88hKOzh8/6LWWcrnJ7HceL1aFvKuqCj3g2Ric5S77F34ZoxpG7n1ikpdFX6vbyFFtabRSj1f2b5/IBwp/IzFUfrXM0v1Uqbz8CvXIAoFPVs7AYLet5fbnFbJgVs6wdMcsq6lJtTW3MCtn8NOgLpbIj+WXM1Tu/WudhWElUXYcn9r6N5R5223NorKuOhvSAp24gmUBfgn55M4btpJYxmqF5/Xy5b5d9XyFs9yN3iL8Cs2iWCoIcqwemcfeUvLJHTf2ZykY3GMRVAbtsgY6qDK5nSIWWZYLG1nN3pK107Jmd0opWErUa8114RJjoVav7DqGbOkFyK/5jJn3akSjsyEUnB8q5GQbMsot8749Cd1SFzJlodP/jVneDqGL7OpNXB65K9MpMGe+2q28xERhTv1GpufdvBqcY/qfW865g3kbHhVl1sqwpDUWJbBA1uCjSBigUzpGLG6FrkFEKdNFGNo4k1lm7AWD5PmkhzLfBPDmy1Hpu1E3o5Stzwsj78br4Wk2Z97Mn/sG5ZX+nskv83zSqaxMZqV5ub5ktLH8RREwhyy2+8Wi9ml9G4YxL72YSReThhm5fyjP6HriXk86llX+5tseb1XUO1murDzzKBueKdaP7UeGfWRJWDRdpFeM9MUamWY5yo4iGB/M02hcUxD1a8wNsDSHLbV4wECQD7RAIA9JkXyvm3xQMaY431iLAFGeo1/Dxsf4v8jNIAUF8s7yAZELIOUkEgTUKvBRIGXkQ5T4OiFDy2xoE3khCoExyIuQDPJiUmeG685w2heok6KAe00SLfXFUECT0aOVIy3q1TeokMSnHuuhceEKQwlC6k0oMpIhYw2g1atdq0fZxsAbjPmDZhrkFqyDhY/Dhnl+D7jxpZyYAf4A3MRDI5f7tWHGf3YM0s/n931P8cXYlTY8Dk9MZSewWm+U8sEZ5eT82GQ2P9aUBlJ2lqh8YWyyRSmz4i9DuVAaMlfDezjYGsgFtupFuO49TdmXP0kPbhCOZwAeC2QD6831nbbK6Onus7bhx3OYzJW7Bub0Q0OZHSD3wbvPQv63EBiFcEAnuCYKjTszmRcKJ0ai8LcciLvwVSJI6gekj0fF7lSUHKll5EyfM7MHJ8hlj+QhJ0BgBEYNzHDdP88PvFf5Ynv3sbWzeJSNwsh2U32jUSqjUKRV7FsUDPb7t+SH5+d74tLarJClp/gc3eA/spHWzUFkXCWn5/HuYA6kjkmxN144qV6glBkutzLLt+UXMLNLZ/H0QU5xeSN1HmXrmyd0cps4Gi9V1BXiyxmWH9fX8ecAolwEO8hBSVuv05btojPvNJ0zkifi8XgO4LK6Na/aqlLLiiCyONGEK21ADZgaM6s3MeOm3w1OKzVJ6r+S7QOqRMbFFRWxMCw/FrkREuY+swX/mxVhOAvQmZE2qKViNHqqYF0ED+QhKuJQ+X9GduknVfyrUgamC0yYm8iQ73/x1+HpgRNhEw5LBjOSFmMEMtFnlY/8PtA5hoOZB0TofMBaX7aTysisnKEMhLraSSwcHhzBRtjK7Z4DuD1ym2YrL2/nI8r30DnlQ7Y9LfzMAXzVF9oJyV3txqq2KGUqzGUKppppzWcG8b1lfI2QxfddU5H2R9TSZsSrgchfz3Tgop41/GyPtb65LL97jsXlDKsazJczMCtnYGBWzsDArJyBgVk5AwOzcgYGZuUMDMzKGRiYlTMwK2dgWAn4f41ThZWzv3ygAAAAAElFTkSuQmCC</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2008-08-25 14:10:00 +0200" MODIFIED_BY="Nicole Skoetz" NO="3" REF_ID="CMP-002.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Length of neutropenia, outcome: 2.2 Length of neutropenia excluding Michel 2000.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2008-08-25 14:10:06 +0200" MODIFIED_BY="Nicole Skoetz" NO="4" REF_ID="CMP-003.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Length of hospitalisation, outcome: 3.1 Length of hospitalisation.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2009-02-12 16:28:29 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-005.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Number of infectious disease episodes, outcome: 5.1 Number of infectious disease episodes.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2008-08-25 14:27:22 +0200" MODIFIED_BY="Nicole Skoetz" NO="6" REF_ID="CMP-004.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Delays in chemotherapy courses, outcome: 4.1 Number of delays in chemotherapy.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-08-25 13:48:53 +0200" MODIFIED_BY="Nicole Skoetz">
<APPENDIX ID="APP-01" MODIFIED="2008-08-25 13:48:53 +0200" MODIFIED_BY="Nicole Skoetz" NO="1">
<TITLE MODIFIED="2008-08-25 13:48:49 +0200" MODIFIED_BY="Nicole Skoetz">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-08-25 13:48:53 +0200" MODIFIED_BY="Nicole Skoetz">
<P>#1 Methodological search strategies<BR/>#2 explode COLONY-STIMULATING-FACTORS / all subheadings<BR/>#3 CSF<BR/>#4 #2 or #3<BR/>#5 explode FEVER / all subheadings<BR/>#6 FEVER* or FEBR*<BR/>#7 #5 or #6<BR/>#8 #4 and #7<BR/>#9 #1 and #8</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>